BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bréchot C, Thiers V, Kremsdorf D, Nalpas B, Pol S, Paterlini-Bréchot P. Persistent hepatitis B virus infection in subjects without hepatitis B surface antigen: clinically significant or purely “occult”? Hepatology. 2001;34:194-203. [PMID: 11431751 DOI: 10.1053/jhep.2001.25172] [Cited by in Crossref: 377] [Cited by in F6Publishing: 381] [Article Influence: 18.9] [Reference Citation Analysis]
Number Citing Articles
1 Ghisetti V, Marzano A, Zamboni F, Barbui A, Franchello A, Gaia S, Marchiaro G, Salizzoni M, Rizzetto M. Occult hepatitis B virus infection in HBsAg negative patients undergoing liver transplantation: clinical significance. Liver Transpl. 2004;10:356-362. [PMID: 15004761 DOI: 10.1002/lt.20093] [Cited by in Crossref: 40] [Cited by in F6Publishing: 39] [Article Influence: 2.4] [Reference Citation Analysis]
2 Urbani S, Fagnoni F, Missale G, Franchini M. The role of anti-core antibody response in the detection of occult hepatitis B virus infection. Clin Chem Lab Med. 2010;48:23-29. [PMID: 19919328 DOI: 10.1515/cclm.2010.002] [Cited by in Crossref: 32] [Cited by in F6Publishing: 22] [Article Influence: 2.9] [Reference Citation Analysis]
3 Mardian Y, Yano Y, Wasityastuti W, Ratnasari N, Liang Y, Putri WA, Triyono T, Hayashi Y. Genetic polymorphisms of HLA-DP and isolated anti-HBc are important subsets of occult hepatitis B infection in Indonesian blood donors: a case-control study. Virol J 2017;14:201. [PMID: 29061159 DOI: 10.1186/s12985-017-0865-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
4 Carimo AA, Gudo ES, Maueia C, Mabunda N, Chambal L, Vubil A, Flora A, Antunes F, Bhatt N. First report of occult hepatitis B infection among ART naïve HIV seropositive individuals in Maputo, Mozambique. PLoS One 2018;13:e0190775. [PMID: 29320552 DOI: 10.1371/journal.pone.0190775] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
5 Choi HN, Song JE, Lee HC, Jo HH, Lee CH, Kim BS. Efficacy of prolonged entecavir monotherapy in treatment-naïve chronic hepatitis B patients exhibiting a partial virologic response to entecavir. Clin Mol Hepatol 2015;21:24-31. [PMID: 25834799 DOI: 10.3350/cmh.2015.21.1.24] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
6 Chen MH, Hsiao LT, Chiou TJ, Liu JH, Gau JP, Teng HW, Wang WS, Chao TC, Yen CC, Chen PM. High prevalence of occult hepatitis B virus infection in patients with B cell non-Hodgkin's lymphoma. Ann Hematol 2008;87:475-80. [PMID: 18327583 DOI: 10.1007/s00277-008-0469-9] [Cited by in Crossref: 64] [Cited by in F6Publishing: 64] [Article Influence: 4.9] [Reference Citation Analysis]
7 Dalia S, Dunker K, Sokol L, Mhaskar R. Hepatitis B seropositivity and risk of developing multiple myeloma or Hodgkin lymphoma: A meta-analysis of observational studies. Leuk Res 2015;39:1325-33. [PMID: 26394533 DOI: 10.1016/j.leukres.2015.09.008] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
8 Lo Re V 3rd, Wertheimer B, Localio AR, Kostman JR, Dockter J, Linnen JM, Giachetti C, Dorey-Stein Z, Frank I, Strom BL, Gross R. Incidence of transaminitis among HIV-infected patients with occult hepatitis B. J Clin Virol 2008;43:32-6. [PMID: 18486540 DOI: 10.1016/j.jcv.2008.03.030] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
9 Wai CT, Fontana RJ. Clinical significance of hepatitis B virus genotypes, variants, and mutants. Clin Liver Dis 2004;8:321-52, vi. [PMID: 15481343 DOI: 10.1016/j.cld.2004.02.006] [Cited by in Crossref: 47] [Cited by in F6Publishing: 38] [Article Influence: 2.8] [Reference Citation Analysis]
10 Ioannou GN, Splan MF, Weiss NS, McDonald GB, Beretta L, Lee SP. Incidence and predictors of hepatocellular carcinoma in patients with cirrhosis. Clin Gastroenterol Hepatol 2007; 5: 938-945, 945.e1-945. e4. [PMID: 17509946 DOI: 10.1016/j.cgh.2007.02.039] [Cited by in Crossref: 140] [Cited by in F6Publishing: 123] [Article Influence: 10.0] [Reference Citation Analysis]
11 French AL, Operskalski E, Peters M, Strickler HD, Tien PC, Sharp GB, Glesby MJ, Young M, Augenbraun M, Seaberg E, Kovacs A. Isolated hepatitis B core antibody is associated with HIV and ongoing but not resolved hepatitis C virus infection in a cohort of US women. J Infect Dis 2007;195:1437-42. [PMID: 17436223 DOI: 10.1086/515578] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 1.9] [Reference Citation Analysis]
12 Laguno M, Larrousse M, Blanco JL, Leon A, Milinkovic A, Martínez-Rebozler M, Loncá M, Martinez E, Sanchez-Tapias JM, de Lazzari E. Prevalence and clinical relevance of occult hepatitis B in the fibrosis progression and antiviral response to INF therapy in HIV-HCV-coinfected patients. AIDS Res Hum Retroviruses. 2008;24:547-553. [PMID: 18393687 DOI: 10.1089/aid.2007.9994] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
13 Yao QQ, Dong XL, Wang XC, Ge SX, Hu AQ, Liu HY, Wang YA, Yuan Q, Zheng YJ. Hepatitis B virus surface antigen (HBsAg)-positive and HBsAg-negative hepatitis B virus infection among mother-teenager pairs 13 years after neonatal hepatitis B virus vaccination. Clin Vaccine Immunol. 2013;20:269-275. [PMID: 23254298 DOI: 10.1128/cvi.00539-12] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
14 European Association For The Study Of The Liver. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol. 2012;57:167-185. [PMID: 22436845 DOI: 10.1016/j.jhep.2012.02.010] [Cited by in Crossref: 2167] [Cited by in F6Publishing: 2020] [Article Influence: 240.8] [Reference Citation Analysis]
15 Rao W, Xie M, Yang T, Zhang JJ, Gao W, Deng YL, Zheng H, Pan C, Liu YH, Shen ZY. Risk factors for de novo hepatitis B infection in pediatric living donor liver transplantation. World J Gastroenterol. 2014;20:13159-13166. [PMID: 25278711 DOI: 10.3748/wjg.v20.i36.13159] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
16 Olsen S, Brown R. Hepatitis B treatment: Lessons for the nephrologist. Kidney International 2006;70:1897-904. [DOI: 10.1038/sj.ki.5001908] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
17 Katsoulidou A, Paraskevis D, Magiorkinis E, Moschidis Z, Haida C, Hatzitheodorou E, Varaklioti A, Karafoulidou A, Hatzitaki M, Kavallierou L. Molecular characterization of occult hepatitis B cases in Greek blood donors. J Med Virol. 2009;81:815-825. [PMID: 19319945 DOI: 10.1002/jmv.21499] [Cited by in Crossref: 37] [Cited by in F6Publishing: 41] [Article Influence: 3.1] [Reference Citation Analysis]
18 Datta S, Chatterjee S, Policegoudra RS, Gogoi HK, Singh L. Hepatitis viruses and non-Hodgkin's lymphoma: A review. World J Virol 2012;1:162-73. [PMID: 24175222 DOI: 10.5501/wjv.v1.i6.162] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
19 Albuquerque ACCD, Coelho MRCD, Lemos MF, Moreira RC. Occult hepatitis B virus infection in hemodialysis patients in Recife, State of Pernambuco, Brazil. Rev Soc Bras Med Trop 2012;45:558-62. [DOI: 10.1590/s0037-86822012000500004] [Cited by in Crossref: 14] [Cited by in F6Publishing: 3] [Article Influence: 1.6] [Reference Citation Analysis]
20 Raimondo G, Allain J, Brunetto MR, Buendia M, Chen D, Colombo M, Craxì A, Donato F, Ferrari C, Gaeta GB, Gerlich WH, Levrero M, Locarnini S, Michalak T, Mondelli MU, Pawlotsky J, Pollicino T, Prati D, Puoti M, Samuel D, Shouval D, Smedile A, Squadrito G, Trépo C, Villa E, Will H, Zanetti AR, Zoulim F. Statements from the Taormina expert meeting on occult hepatitis B virus infection. Journal of Hepatology 2008;49:652-7. [DOI: 10.1016/j.jhep.2008.07.014] [Cited by in Crossref: 513] [Cited by in F6Publishing: 487] [Article Influence: 39.5] [Reference Citation Analysis]
21 Allain JP. Occult hepatitis B virus infection: implications in transfusion. Vox Sang. 2004;86:83-91. [PMID: 15023176 DOI: 10.1111/j.0042-9007.2004.00406.x] [Cited by in Crossref: 192] [Cited by in F6Publishing: 182] [Article Influence: 11.3] [Reference Citation Analysis]
22 Minuk GY, Sun DF, Uhanova J, Zhang M, Caouette S, Nicolle LE, Gutkin A, Doucette K, Martin B, Giulivi A. Occult hepatitis B virus infection in a North American community-based population. J Hepatol. 2005;42:480-485. [PMID: 15763333 DOI: 10.1016/j.jhep.2004.11.037] [Cited by in Crossref: 65] [Cited by in F6Publishing: 62] [Article Influence: 4.1] [Reference Citation Analysis]
23 Raimondo G, Pollicino T, Squadrito G. Clinical virology of hepatitis B virus infection. Journal of Hepatology 2003;39:26-30. [DOI: 10.1016/s0168-8278(03)00135-1] [Cited by in Crossref: 16] [Cited by in F6Publishing: 2] [Article Influence: 0.9] [Reference Citation Analysis]
24 Hasegawa I, Orito E, Tanaka Y, Hirashima N, Sakakibara K, Sakurai M, Suzuki S, Sugauchi F, Ohno T, Ueda R. Impact of occult hepatitis B virus infection on efficacy and prognosis of interferon-alpha therapy for patients with chronic hepatitis C. Liver Int. 2005;25:247-253. [PMID: 15780046 DOI: 10.1111/j.1478-3231.2005.1096.x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 1.6] [Reference Citation Analysis]
25 Bowden S, Bartholomeusz A, Locarnini S. Lamivudine resistant occult HBV: implications for public health? J Hepatol. 2003;38:526-528. [PMID: 12663248 DOI: 10.1016/s0168-8278(03)00079-5] [Cited by in Crossref: 10] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
26 Hu Z, Li M, Liu J, Yu L, Xue Y, Chen Y. Detection of Hepatitis B Virus Large Surface Protein Using a Time-Resolved Immunofluorometric Assay. J Clin Lab Anal 2015;29:498-504. [PMID: 25277704 DOI: 10.1002/jcla.21800] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
27 Candotti D, Etiz N, Parsyan A, Allain JP. Identification and characterization of persistent human erythrovirus infection in blood donor samples. J Virol 2004;78:12169-78. [PMID: 15507603 DOI: 10.1128/JVI.78.22.12169-12178.2004] [Cited by in Crossref: 126] [Cited by in F6Publishing: 33] [Article Influence: 7.4] [Reference Citation Analysis]
28 Foaud H, Maklad S, Mahmoud F, El-karaksy H. Occult hepatitis B virus infection in children born to HBsAg-positive mothers after neonatal passive-active immunoprophylaxis. Infection 2015;43:307-14. [DOI: 10.1007/s15010-015-0733-6] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
29 Kupski C, Träsel FR, Mazzoleni F, Winckler MA, Bender AL, Machado DC, Schmitt VM. Serologic and Molecular Profile of Anti-HBc-Positive Blood Bank Donors in an Area of Low Endemicity for HBV. Dig Dis Sci 2008;53:1370-4. [DOI: 10.1007/s10620-007-0019-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
30 Ozaslan E, Demirezer A, Yavuz B. Occult hepatitis B virus infection in Turkish healthy individuals. Eur J Gastroenterol Hepatol 2009;21:1436-7. [PMID: 19907228 DOI: 10.1097/10.1097/MEG.0b013e328321b124] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
31 Kim MJ, Kwon OS, Chung NS, Lee SY, Jung HS, Park DK, Ku YS, Kim YK, Kim YS, Kim JH. [The significance of anti-HBc and occult hepatitis B virus infection in the occurrence of hepatocellular carcinoma in patients with HBsAg and anti-HCV negative alcoholic cirrhosis]. Korean J Hepatol. 2008;14:67-76. [PMID: 18367859 DOI: 10.3350/kjhep.2008.14.1.67] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
32 Alencar R, Gomes M, Sitnik R, Pinho J, Malta F, Mello I, Mello E, Bacchella T, Machado M, Alves V, Carrilho F. Low occurrence of occult hepatitis B virus infection and high frequency of hepatitis C virus genotype 3 in hepatocellular carcinoma in Brazil. Braz J Med Biol Res 2008;41:235-40. [DOI: 10.1590/s0100-879x2006005000197] [Cited by in Crossref: 16] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
33 Levrero M, Pollicino T, Petersen J, Belloni L, Raimondo G, Dandri M. Control of cccDNA function in hepatitis B virus infection. J Hepatol. 2009;51:581-592. [PMID: 19616338 DOI: 10.1016/j.jhep.2009.05.022] [Cited by in Crossref: 353] [Cited by in F6Publishing: 325] [Article Influence: 29.4] [Reference Citation Analysis]
34 Gujar SA, Michalak TI. Primary occult hepadnavirus infection induces virus-specific T-cell and aberrant cytokine responses in the absence of antiviral antibody reactivity in the Woodchuck model of hepatitis B virus infection. J Virol 2009;83:3861-76. [PMID: 19193791 DOI: 10.1128/JVI.02521-08] [Cited by in Crossref: 21] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
35 Huang X, Qin Y, Li W, Shi Q, Xue Y, Li J, Liu C, Hollinger FB, Shen Q. Molecular analysis of the hepatitis B virus presurface and surface gene in patients from eastern China with occult hepatitis B. J Med Virol. 2013;85:979-986. [PMID: 23588723 DOI: 10.1002/jmv.23556] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
36 Kusakabe A, Tanaka Y, Orito E, Sugauchi F, Kurbanov F, Sakamoto T, Shinkai N, Hirashima N, Hasegawa I, Ohno T. A weak association between occult HBV infection and non-B non-C hepatocellular carcinoma in Japan. J Gastroenterol. 2007;42:298-305. [PMID: 17464459 DOI: 10.1007/s00535-006-1999-3] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 1.6] [Reference Citation Analysis]
37 Portilho MM, Nabuco LC, Villela-Nogueira CA, Brandão-Mello CE, Pilotto JH, Flores GL, Lewis-Ximenez LL, Lampe E, Villar LM. Detection of occult hepatitis B in serum and oral fluid samples. Mem Inst Oswaldo Cruz 2018;113:62-5. [PMID: 29211108 DOI: 10.1590/0074-02760170071] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
38 Pollicino T, Raffa G, Costantino L, Lisa A, Campello C, Squadrito G, Levrero M, Raimondo G. Molecular and functional analysis of occult hepatitis B virus isolates from patients with hepatocellular carcinoma. Hepatology. 2007;45:277-285. [PMID: 17256766 DOI: 10.1002/hep.21529] [Cited by in Crossref: 109] [Cited by in F6Publishing: 107] [Article Influence: 7.8] [Reference Citation Analysis]
39 Tani Y, Aso H, Matsukura H, Tadokoro K, Tamori A, Nishiguchi S, Yoshizawa H, Shibata H. Significant background rates of HBV and HCV infections in patients and risks of blood transfusion from donors with low anti-HBc titres or high anti-HBc titres with high anti-HBs titres in Japan: a prospective, individual NAT study of transfusion-transmitted HBV, HCV and HIV infections. Vox Sang. 2012;102:285-293. [PMID: 22082342 DOI: 10.1111/j.1423-0410.2011.01561.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
40 Aghakhani A, Banifazl M, Kalantar E, Eslamifar A, Ahmadi F, Razeghi E, Atabak S, Amini M, Khadem-Sadegh A, Ramezani A. Occult hepatitis B virus infection in hemodialysis patients with isolated hepatitis B core antibody: a multicenter study. Ther Apher Dial. 2010;14:349-353. [PMID: 20609190 DOI: 10.1111/j.1744-9987.2009.00798.x] [Cited by in Crossref: 42] [Cited by in F6Publishing: 38] [Article Influence: 3.8] [Reference Citation Analysis]
41 Myers RP, Thibault V, Poynard T. The impact of prior hepatitis B virus infection on liver histology and the response to interferon therapy in chronic hepatitis C. J Viral Hepat. 2003;10:103-110. [PMID: 12614466 DOI: 10.1046/j.1365-2893.2003.00407.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
42 Bhattacharya P, Chandra PK, Datta S, Banerjee A, Chakraborty S, Rajendran K, Basu SK, Bhattacharya SK, Chakravarty R. Significant increase in HBV, HCV, HIV and syphilis infections among blood donors in West Bengal, Eastern India 2004-2005: exploratory screening reveals high frequency of occult HBV infection. World J Gastroenterol. 2007;13:3730-3733. [PMID: 17659734 DOI: 10.3748/wjg.v13.i27.3730] [Cited by in CrossRef: 43] [Cited by in F6Publishing: 47] [Article Influence: 3.1] [Reference Citation Analysis]
43 Diarra B, Yonli AT, Sorgho PA, Compaore TR, Ouattara AK, Zongo WA, Tao I, Traore L, Soubeiga ST, Djigma FW. Occult Hepatitis B Virus Infection and Associated Genotypes among HBsAg-negative Subjects in Burkina Faso. Mediterr J Hematol Infect Dis. 2018;10:e2018007. [PMID: 29326804 DOI: 10.4084/mjhid.2018.007] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
44 Fabrizi F, Lunghi G, Martin P, Poordad F. Serological and Molecular Testing in Hepatitis B and the Dialysis Patient. Int J Artif Organs 2002;25:91-9. [DOI: 10.1177/039139880202500203] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
45 Karaosmanoglu HK, Aydin OA, Nazlican O. Isolated anti-HBc among HIV-infected patients in Istanbul, Turkey. HIV Clin Trials 2013;14:17-20. [PMID: 23372111 DOI: 10.1310/hct1401-17] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
46 Neau D, Winnock M, Jouvencel AC, Faure M, Castéra L, Legrand E, Lacoste D, Ragnaud JM, Dupon M, Fleury H. Occult hepatitis B virus infection in HIV-infected patients with isolated antibodies to hepatitis B core antigen: Aquitaine cohort, 2002-2003. Clin Infect Dis. 2005;40:750-753. [PMID: 15714424 DOI: 10.1086/427882] [Cited by in Crossref: 47] [Cited by in F6Publishing: 51] [Article Influence: 2.9] [Reference Citation Analysis]
47 Mu SC, Lin YM, Jow GM, Chen BF. Occult hepatitis B virus infection in hepatitis B vaccinated children in Taiwan. J Hepatol. 2009;50:264-272. [PMID: 19070923 DOI: 10.1016/j.jhep.2008.09.017] [Cited by in Crossref: 72] [Cited by in F6Publishing: 73] [Article Influence: 5.5] [Reference Citation Analysis]
48 Sofian M, Aghakhani A, Izadi N, Banifazl M, Kalantar E, Eslamifar A, Ramezani A. Lack of occult hepatitis B virus infection among blood donors with isolated hepatitis B core antibody living in an HBV low prevalence region of Iran. Int J Infect Dis 2010;14:e308-10. [PMID: 19656713 DOI: 10.1016/j.ijid.2009.05.011] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 1.3] [Reference Citation Analysis]
49 Dong C, Song Z, Chen J, Ma N, Meng X, Sun C, Duan K, Bi B, Wang K, Qin H, Han C, Yang Y, Zhang F, Zheng W, Gao W. Risk factors of de novo hepatitis B virus infection in pediatric hepatitis B core antibody positive liver graft recipients under prophylactic therapy. J Gastroenterol Hepatol 2020;35:827-32. [PMID: 31609494 DOI: 10.1111/jgh.14869] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
50 Almeida RP, Cardoso DD. Detection of HBV DNA by nested-PCR in a HBsAg and anti-HBc negative blood bank donor. J Clin Virol 2006;36:231-4. [PMID: 16574475 DOI: 10.1016/j.jcv.2006.02.004] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.0] [Reference Citation Analysis]
51 Gaeta GB, Precone DF, Cozzi-lepri A, Cicconi P, Monforte AD. Multiple viral infections. Journal of Hepatology 2006;44:S108-13. [DOI: 10.1016/j.jhep.2005.11.023] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 1.3] [Reference Citation Analysis]
52 Tan HH, Martin P. Management of end-stage liver disease in chronic hepatitis B. Clin Liver Dis. 2010;14:477-493. [PMID: 20638026 DOI: 10.1016/j.cld.2010.05.006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
53 Chakvetadze C, Bani-Sadr F, Le Pendeven C, Lamontagne F, Vincensini JP, Pialoux G. Reactivation of hepatitis B virus replication during peginterferon-ribavirin therapy in an HIV/hepatitis C virus-co-infected patient with isolated anti-hepatitis B core antibodies. AIDS. 2007;21:393-394. [PMID: 17255759 DOI: 10.1097/qad.0b013e328012b5d3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
54 Salpini R, Piermatteo L, Gill U, Battisti A, Stazi F, Guenci T, Giannella S, Serafini V, Kennedy PTF, Perno CF, Svicher V, Ciotti M. Quantification of intrahepatic total HBV DNA in liver biopsies of HBV-infected patients by a modified version of COBAS® Ampliprep/COBAS®TaqMan HBV test v2.0. Med Microbiol Immunol 2017;206:295-9. [PMID: 28401351 DOI: 10.1007/s00430-017-0504-3] [Reference Citation Analysis]
55 Bernieh B. Viral hepatitis in hemodialysis: An update. J Transl Int Med. 2015;3:93-105. [PMID: 27847896 DOI: 10.1515/jtim-2015-0018] [Cited by in Crossref: 26] [Cited by in F6Publishing: 18] [Article Influence: 4.3] [Reference Citation Analysis]
56 Lu J, Gong W, Cheng H, Wu Z, Li D, Wang X, Liang P, Zhang J. Detection of HBV genotypes of tumor tissues and serum by a fluorescence polarization assay in north-western China’s hepatocellular carcinoma patients. Virol J. 2011;8:362. [PMID: 21781311 DOI: 10.1186/1743-422x-8-362] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
57 Chen X, Xiang K, Zhang H, Kong X, Huang C, Liu Y, Lou J, Gao Z, Yan H. Occult HBV infection in patients with autoimmune hepatitis: A virological and clinical study. Journal of Microbiology, Immunology and Infection 2020;53:946-54. [DOI: 10.1016/j.jmii.2019.04.009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
58 Wang N, Zhang D, Zhao W, Li B, Lin C. Hepatitis B virus large surface protein in serum as a candidate biomarker for evaluating hepatitis B virus infection. Clinical Biochemistry 2011;44:1199-204. [DOI: 10.1016/j.clinbiochem.2011.07.002] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
59 Ikeda K, Kobayashi M, Someya T, Saitoh S, Hosaka T, Akuta N, Suzuki F, Suzuki Y, Arase Y, Kumada H. Occult hepatitis B virus infection increases hepatocellular carcinogenesis by eight times in patients with non-B, non-C liver cirrhosis: a cohort study. J Viral Hepat. 2009;16:437-443. [PMID: 19226331 DOI: 10.1111/j.1365-2893.2009.01085.x] [Cited by in Crossref: 50] [Cited by in F6Publishing: 50] [Article Influence: 4.2] [Reference Citation Analysis]
60 Gonçales FL Jr, Pereira JS, Da Silva C, Thomaz GR, Pavan MH, Fais VC, Magna LA, Gonçales NS. Hepatitis B virus DNA in sera of blood donors and of patients infected with hepatitis C virus and human immunodeficiency virus. Clin Diagn Lab Immunol 2003;10:718-20. [PMID: 12853411 DOI: 10.1128/cdli.10.4.718-720.2003] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
61 Kannangai R, Molmenti E, Arrazola L, Klein A, Choti M, Thomas DL, Torbenson M. Occult hepatitis B viral DNA in liver carcinomas from a region with a low prevalence of chronic hepatitis B infection. J Viral Hepat. 2004;11:297-301. [PMID: 15230851 DOI: 10.1111/j.1365-2893.2004.00502.x] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 1.7] [Reference Citation Analysis]
62 Pérez-Rodríguez MT, Sopeña B, Crespo M, Rivera A, González del Blanco T, Ocampo A, Martínez-Vázquez C. Clinical significance of "anti-HBc alone" in human immunodeficiency virus-positive patients. World J Gastroenterol 2009;15:1237-41. [PMID: 19291824 DOI: 10.3748/wjg.15.1237] [Cited by in CrossRef: 20] [Cited by in F6Publishing: 21] [Article Influence: 1.7] [Reference Citation Analysis]
63 Asli M, Kandelouei T, Rahimyan K, Davoodbeglou F, Vaezjalali M. Characterization of Occult Hepatitis B Infection Among Injecting Drug Users in Tehran, Iran. Hepat Mon 2016;16:e34763. [PMID: 27226802 DOI: 10.5812/hepatmon.34763] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
64 Mhalla S, Hammoud R, Frih A, Kadri Y, El Argoubi A, Elmay M, Mastouri M. Prevalence and risk factors of hepatitis B and C among hemodialysis patients in Tunisia. Med Mal Infect 2018;48:175-9. [PMID: 29249466 DOI: 10.1016/j.medmal.2017.11.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
65 Silva CM, Costi C, Costa C, Michelon C, Oravec R, Ramos AB, Niel C, Rossetti ML. Low rate of occult hepatitis B virus infection among anti-HBc positive blood donors living in a low prevalence region in Brazil. J Infect 2005;51:24-9. [PMID: 15979486 DOI: 10.1016/j.jinf.2004.07.007] [Cited by in Crossref: 19] [Cited by in F6Publishing: 23] [Article Influence: 1.1] [Reference Citation Analysis]
66 Olotu AA, Oyelese AO, Salawu L, Audu RA, Okwuraiwe AP, Aboderin AO. Occult Hepatitis B virus infection in previously screened, blood donors in Ile-Ife, Nigeria: implications for blood transfusion and stem cell transplantation. Virol J 2016;13:76. [PMID: 27150469 DOI: 10.1186/s12985-016-0533-3] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
67 Broquetas T, Garcia-Retortillo M, Micó M, Canillas L, Puigvehí M, Cañete N, Coll S, Viu A, Hernandez JJ, Bessa X, Carrión JA. Hepatitis B surface antigen and hepatitis B core-related antigen kinetics after adding pegylated-interferon to nucleos(t)ids analogues in hepatitis B e antigen-negative patients. World J Hepatol 2020;12:1076-88. [PMID: 33312431 DOI: 10.4254/wjh.v12.i11.1076] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
68 Kampfrath T, Jortani SA, Levinson SS. Resolving a case of concurrent hepatitis B virus surface antigen (HBsAg) and surface antibody (HBsAb). Clinica Chimica Acta 2014;430:171-2. [DOI: 10.1016/j.cca.2014.01.016] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
69 Lo Re V, Frank I, Gross R, Dockter J, Linnen JM, Giachetti C, Tebas P, Stern J, Synnestvedt M, Localio AR. Prevalence, risk factors, and outcomes for occult hepatitis B virus infection among HIV-infected patients. J Acquir Immune Defic Syndr. 2007;44:315-320. [PMID: 17159655 DOI: 10.1097/qai.0b013e31802ea499] [Cited by in Crossref: 47] [Cited by in F6Publishing: 26] [Article Influence: 3.4] [Reference Citation Analysis]
70 Sagnelli E, Imparato M, Coppola N, Pisapia R, Sagnelli C, Messina V, Piai G, Stanzione M, Bruno M, Moggio G, Caprio N, Pasquale G, Del Vecchio Blanco C. Diagnosis and clinical impact of occult hepatitis B infection in patients with biopsy proven chronic hepatitis C: a multicenter study. J Med Virol. 2008;80:1547-1553. [PMID: 18649338 DOI: 10.1002/jmv.21239] [Cited by in Crossref: 47] [Cited by in F6Publishing: 43] [Article Influence: 3.6] [Reference Citation Analysis]
71 Emara MH, El-Gammal NE, Mohamed LA, Bahgat MM. Occult hepatitis B infection in egyptian chronic hepatitis C patients: prevalence, impact on pegylated interferon/ribavirin therapy. Virol J. 2010;7:324. [PMID: 21083926 DOI: 10.1186/1743-422x-7-324] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
72 Inoue T, Tanaka Y. The Role of Hepatitis B Core-Related Antigen. Genes (Basel) 2019;10:E357. [PMID: 31075974 DOI: 10.3390/genes10050357] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 7.0] [Reference Citation Analysis]
73 Pereira AA, Jacobson IM. Modern diagnosis of HBV infection. Curr hepatitis rep 2009;8:18-25. [DOI: 10.1007/s11901-009-0003-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
74 Toyoda H, Kumada T, Kiriyama S, Sone Y, Tanikawa M, Hisanaga Y, Kanamori A. Prevalence of low-level hepatitis B viremia in patients with HBV surface antigen-negative hepatocellular carcinoma with and without hepatitis C virus infection in Japan: analysis by COBAS TaqMan real-time PCR. Intervirology. 2007;50:241-244. [PMID: 17446712 DOI: 10.1159/000101911] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 0.8] [Reference Citation Analysis]
75 Wietzke-braun P, Maouzi AB, M??nhardt LB, Bickeb??ller H, Ramadori G, Mihm S. Interferon regulatory factor-1 promoter polymorphism and the outcome of hepatitis C virus infection: . European Journal of Gastroenterology & Hepatology 2006;18:991-7. [DOI: 10.1097/01.meg.0000224478.89545.76] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 1.3] [Reference Citation Analysis]
76 Gupta S, Singh S. Occult hepatitis B virus infection in ART-naive HIV-infected patients seen at a tertiary care centre in north India. BMC Infect Dis. 2010;10:53. [PMID: 20205948 DOI: 10.1186/1471-2334-10-53] [Cited by in Crossref: 44] [Cited by in F6Publishing: 41] [Article Influence: 4.0] [Reference Citation Analysis]
77 Arababadi MK, Hassanshahi G, Pourfathollah AA, Zarandi ER, Kennedy D. Post-transfusion occult hepatitis B (OBI): a global challenge for blood recipients and health authorities. Hepat Mon. 2011;11:714-718. [PMID: 22235213 DOI: 10.5812/kowsar.1735143x.694] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
78 Yuen MF, Wong DK, Fung J, Ip P, But D, Hung I, Lau K, Yuen JC, Lai CL. HBsAg Seroclearance in chronic hepatitis B in Asian patients: replicative level and risk of hepatocellular carcinoma. Gastroenterology. 2008;135:1192-1199. [PMID: 18722377 DOI: 10.1053/j.gastro.2008.07.008] [Cited by in Crossref: 276] [Cited by in F6Publishing: 237] [Article Influence: 21.2] [Reference Citation Analysis]
79 Bielawski KP, Stalke P. Molecular epidemiology of chronic hepatitis B virus infection in northern Poland. J Clin Virol. 2005;34 Suppl 1:S63-S69. [PMID: 16461226 DOI: 10.1016/s1386-6532(05)80012-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
80 Jang JY, Park EJ. [Occult hepatitis B virus infection in chronic hepatitis C]. Korean J Gastroenterol 2013;62:154-9. [PMID: 24077625 DOI: 10.4166/kjg.2013.62.3.154] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
81 Zobeiri M. Occult hepatitis B: clinical viewpoint and management. Hepat Res Treat. 2013;2013:259148. [PMID: 23533738 DOI: 10.1155/2013/259148] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
82 Bagaglio S, Porrino L, Lazzarin A, Morsica G. Molecular characterization of occult and overt hepatitis B (HBV) infection in an HIV-infected person with reactivation of HBV after antiretroviral treatment interruption. Infection 2010;38:417-21. [DOI: 10.1007/s15010-010-0032-1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
83 Pondé RA. Molecular mechanisms underlying HBsAg negativity in occult HBV infection. Eur J Clin Microbiol Infect Dis. 2015;34:1709-1731. [PMID: 26105620 DOI: 10.1007/s10096-015-2422-x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
84 Hui CK, Cheung WW, Zhang HY, Au WY, Yueng YH, Leung AY, Leung N, Luk JM, Lie AK, Kwong YL. Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy. Gastroenterology. 2006;131:59-68. [PMID: 16831590 DOI: 10.1053/j.gastro.2006.04.015] [Cited by in Crossref: 350] [Cited by in F6Publishing: 303] [Article Influence: 23.3] [Reference Citation Analysis]
85 Raimondo G, Locarnini S, Pollicino T, Levrero M, Zoulim F, Lok AS;  Taormina Workshop on Occult HBV Infection Faculty Members. Update of the statements on biology and clinical impact of occult hepatitis B virus infection. J Hepatol. 2019;71:397-408. [PMID: 31004683 DOI: 10.1016/j.jhep.2019.03.034] [Cited by in Crossref: 113] [Cited by in F6Publishing: 89] [Article Influence: 56.5] [Reference Citation Analysis]
86 Wang J, Gujar SA, Cova L, Michalak TI. Bicistronic woodchuck hepatitis virus core and gamma interferon DNA vaccine can protect from hepatitis but does not elicit sterilizing antiviral immunity. J Virol. 2007;81:903-916. [PMID: 17079319 DOI: 10.1128/jvi.01537-06] [Cited by in Crossref: 26] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
87 Torbenson M, Kannangai R, Astemborski J, Strathdee SA, Vlahov D, Thomas DL. High prevalence of occult hepatitis B in Baltimore injection drug users. Hepatology. 2004;39:51-57. [PMID: 14752822 DOI: 10.1002/hep.20025] [Cited by in Crossref: 78] [Cited by in F6Publishing: 74] [Article Influence: 4.6] [Reference Citation Analysis]
88 Kim YS. [Definition, diagnosis, and prevalence of occult hepatitis B virus infection]. Korean J Gastroenterol 2013;62:143-7. [PMID: 24077623 DOI: 10.4166/kjg.2013.62.3.143] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
89 Percy ME, Potyomkina Z, Dalton AJ, Fedor B, Mehta P, Andrews DF, Mazzulli T, Murk L, Warren AC, Wallace RA, Chau H, Jeng W, Moalem S, O'Brien L, Schellenberger S, Tran H, Wu L. Relation between apolipoprotein E genotype, hepatitis B virus status, and thyroid status in a sample of older persons with Down syndrome. Am J Med Genet A 2003;120A:191-8. [PMID: 12833399 DOI: 10.1002/ajmg.a.20099] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 0.7] [Reference Citation Analysis]
90 Larrubia JR. Occult hepatitis B virus infection: a complex entity with relevant clinical implications. World J Gastroenterol. 2011;17:1529-1530. [PMID: 21472115 DOI: 10.3748/wjg.v17.i12] [Reference Citation Analysis]
91 Wong DK, Huang FY, Lai CL, Poon RT, Seto WK, Fung J, Hung IF, Yuen MF. Occult hepatitis B infection and HBV replicative activity in patients with cryptogenic cause of hepatocellular carcinoma. Hepatology. 2011;54:829-836. [PMID: 21809355 DOI: 10.1002/hep.24551] [Cited by in Crossref: 95] [Cited by in F6Publishing: 85] [Article Influence: 9.5] [Reference Citation Analysis]
92 Lok AS, Everhart JE, Di Bisceglie AM, Kim HY, Hussain M, Morgan TR; HALT-C Trial Group. Occult and previous hepatitis B virus infection are not associated with hepatocellular carcinoma in United States patients with chronic hepatitis C. Hepatology. 2011;54:434-442. [PMID: 21374690 DOI: 10.1002/hep.24257] [Cited by in Crossref: 50] [Cited by in F6Publishing: 44] [Article Influence: 5.0] [Reference Citation Analysis]
93 Custer B, Sullivan SD, Hazlet TK, Iloeje U, Veenstra DL, Kowdley KV. Global epidemiology of hepatitis B virus. J Clin Gastroenterol. 2004;38:S158-S168. [PMID: 15602165 DOI: 10.1097/00004836-200411003-00008] [Cited by in Crossref: 362] [Cited by in F6Publishing: 349] [Article Influence: 22.6] [Reference Citation Analysis]
94 Hollinger FB, Sood G. Occult hepatitis B virus infection: a covert operation. J Viral Hepat. 2010;17:1-15. [PMID: 20002296 DOI: 10.1111/j.1365-2893.2009.01245.x] [Cited by in Crossref: 110] [Cited by in F6Publishing: 107] [Article Influence: 9.2] [Reference Citation Analysis]
95 Ohki T, Tateishi R, Goto E, Sato T, Masuzaki R, Imamura J, Goto T, Kanai F, Kato N, Shiina S. Influence of anti-HBc seropositivity on the risk of hepatocellular carcinoma in HCV-infected patients after adjusting for confounding factors. J Viral Hepat. 2010;17:91-97. [PMID: 19566786 DOI: 10.1111/j.1365-2893.2009.01152.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
96 Akram A, Islam SMR, Munshi SU, Tabassum S. Detection of Hepatitis B Virus DNA among Chronic and potential Occult HBV patients in resource-limited settings by Loop-Mediated Isothermal Amplification assay. J Viral Hepat 2018;25:1306-11. [DOI: 10.1111/jvh.12931] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
97 Launay O, Masurel J, Servant-Delmas A, Basse-Guérineau AL, Méritet JF, Laperche S, Sogni P, Rosenberg AR. High levels of serum hepatitis B virus DNA in patients with ‘anti-HBc alone’: role of HBsAg mutants. J Viral Hepat. 2011;18:721-729. [PMID: 21914087 DOI: 10.1111/j.1365-2893.2011.01482.x] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 2.7] [Reference Citation Analysis]
98 Cho J, Lee SS, Choi YS, Jeon Y, Chung JW, Baeg JY, Si WK, Jang ES, Kim JW, Jeong SH. Occult hepatitis B virus infection is not associated with disease progression of chronic hepatitis C virus infection. World J Gastroenterol 2016;22:9427-36. [PMID: 27895431 DOI: 10.3748/wjg.v22.i42.9427] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
99 De Mitri MS, Cassini R, Bernardi M. Hepatitis B virus-related hepatocarcinogenesis: Molecular oncogenic potential of clear or occult infections. European Journal of Cancer 2010;46:2178-86. [DOI: 10.1016/j.ejca.2010.03.034] [Cited by in Crossref: 54] [Cited by in F6Publishing: 55] [Article Influence: 4.9] [Reference Citation Analysis]
100 Zanella I, Rossini A, Domenighini D, Albertini A, Cariani E. Real-time quantitation of hepatitis B virus (HBV) DNA in tumorous and surrounding tissue from patients with hepatocellular carcinoma. J Med Virol. 2002;68:494-499. [PMID: 12376956 DOI: 10.1002/jmv.10243] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 0.7] [Reference Citation Analysis]
101 Pollicino T, Squadrito G, Cerenzia G, Cacciola I, Raffa G, Craxi A, Farinati F, Missale G, Smedile A, Tiribelli C, Villa E, Raimondo G. Hepatitis B virus maintains its pro-oncogenic properties in the case of occult HBV infection. Gastroenterology. 2004;126:102-110. [PMID: 14699492 DOI: 10.1053/j.gastro.2003.10.048] [Cited by in Crossref: 300] [Cited by in F6Publishing: 286] [Article Influence: 17.6] [Reference Citation Analysis]
102 Yang HC, Kao JH. Persistence of hepatitis B virus covalently closed circular DNA in hepatocytes: molecular mechanisms and clinical significance. Emerg Microbes Infect 2014;3:e64. [PMID: 26038757 DOI: 10.1038/emi.2014.64] [Cited by in Crossref: 66] [Cited by in F6Publishing: 71] [Article Influence: 9.4] [Reference Citation Analysis]
103 Taha SE, El-hady SA, Ahmed TM, Ahmed IZ. Detection of occult HBV infection by nested PCR assay among chronic hepatitis C patients with and without hepatocellular carcinoma. Egyptian Journal of Medical Human Genetics 2013;14:353-60. [DOI: 10.1016/j.ejmhg.2013.06.001] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
104 de Castro Sant' Anna C, de Almeida MKC, Ferreira P, de Oliveira RG, Ferreira Baraúna AR, Costa Gonçalvez E, Marinho da Silva A, de Souza Pereira C, Martins LC. Prevalence of occult hepatitis B in a population from the Brazilian Amazon region. J Med Virol 2018;90:1063-70. [PMID: 29446468 DOI: 10.1002/jmv.25051] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
105 Azarkar Z, Ziaee M, Ebrahimzadeh A, Sharifzadeh G, Javanmard D. Epidemiology, risk factors, and molecular characterization of occult hepatitis B infection among anti-hepatitis B core antigen alone subjects. J Med Virol 2019;91:615-22. [PMID: 30345529 DOI: 10.1002/jmv.25343] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
106 Uetake S, Yamauchi M, Itoh S, Kawashima O, Takeda K, Ohata M. Analysis of risk factors for hepatocellular carcinoma in patients with HBs antigen- and anti-HCV antibody-negative alcoholic cirrhosis: clinical significance of prior hepatitis B virus infection. Alcohol Clin Exp Res. 2003;27:47S-51S. [PMID: 12960507 DOI: 10.1097/01.alc.0000079449.47468.b0] [Cited by in Crossref: 36] [Cited by in F6Publishing: 11] [Article Influence: 2.1] [Reference Citation Analysis]
107 Hui C, Lau E, Monto A, Kim M, Luk JM, Poon RTP, Leung N, Lo C, Fan S, Lau GKK, Wright TL. Natural History of Patients with Recurrent Chronic Hepatitis C Virus and Occult Hepatitis B Co-Infection after Liver Transplantation.: In 118 patients with viral and histologic evidence of recurrent hepatitis C infection coinfected with occult hepatitis B virus after liver transplantation, the occult hepatitis B virus coinfection was not associated with accelerated fibrosis. Am J Transplant 2006;6:1600-8. [DOI: 10.1111/j.1600-6143.2006.01370.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 0.9] [Reference Citation Analysis]
108 Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. The Lancet 2003;362:1907-17. [DOI: 10.1016/s0140-6736(03)14964-1] [Cited by in Crossref: 3076] [Cited by in F6Publishing: 1245] [Article Influence: 170.9] [Reference Citation Analysis]
109 Anvari FA, Alavian SM, Norouzi M, Mahabadi M, Jazayeri SM. Prevalence and molecular analysis of occult hepatitis B virus infection isolated in a sample of cryptogenic cirrhosis patients in iran. Oman Med J 2014;29:92-6. [PMID: 24715933 DOI: 10.5001/omj.2014.23] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
110 Comar M, Dal Molin G, D'Agaro P, Crocè SL, Tiribelli C, Campello C. HBV, HCV, and TTV detection by in situ polymerase chain reaction could reveal occult infection in hepatocellular carcinoma: comparison with blood markers. J Clin Pathol. 2006;59:526-529. [PMID: 16537674 DOI: 10.1136/jcp.2005.033050] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 1.9] [Reference Citation Analysis]
111 Coffin CS, Mulrooney-Cousins PM, Peters MG, van Marle G, Roberts JP, Michalak TI, Terrault NA. Molecular characterization of intrahepatic and extrahepatic hepatitis B virus (HBV) reservoirs in patients on suppressive antiviral therapy. J Viral Hepat. 2011;18:415-423. [PMID: 20626626 DOI: 10.1111/j.1365-2893.2010.01321.x] [Cited by in Crossref: 52] [Cited by in F6Publishing: 43] [Article Influence: 5.2] [Reference Citation Analysis]
112 Liu CJ, Chen PJ, Shau WY, Kao JH, Lai MY, Chen DS. Clinical aspects and outcomes of volunteer blood donors testing positive for hepatitis-C virus infection in Taiwan: a prospective study. Liver Int. 2003;23:148-155. [PMID: 12955877 DOI: 10.1034/j.1600-0676.2003.00820.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 0.8] [Reference Citation Analysis]
113 Chang ML, Lin YJ, Chang CJ, Yeh C, Chen TC, Yeh TS, Lee WC, Yeh CT. Occult and Overt HBV Co-Infections Independently Predict Postoperative Prognosis in HCV-Associated Hepatocellular Carcinoma. PLoS One. 2013;8:e64891. [PMID: 23805180 DOI: 10.1371/journal.pone.0064891] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
114 Pondé RA, Cardoso DD, Ferro MO. The underlying mechanisms for the 'anti-HBc alone' serological profile. Arch Virol 2010;155:149-58. [PMID: 20091193 DOI: 10.1007/s00705-009-0559-6] [Cited by in Crossref: 40] [Cited by in F6Publishing: 42] [Article Influence: 3.3] [Reference Citation Analysis]
115 Filippini P, Coppola N, Pisapia R, Scolastico C, Marrocco C, Zaccariello A, Nacca C, Sagnelli C, De Stefano G, Ferraro T, De Stefano C, Sagnelli E. Impact of occult hepatitis B virus infection in HIV patients naive for antiretroviral therapy. AIDS. 2006;20:1253-1260. [PMID: 16816553 DOI: 10.1097/01.aids.0000232232.41877.2a] [Cited by in Crossref: 83] [Cited by in F6Publishing: 80] [Article Influence: 5.5] [Reference Citation Analysis]
116 Wong C, Chan SK, Chan HL, Tsui SK. The Molecular Diagnosis of Hepatitis B Virus-Associated Hepatocellular Carcinoma. Critical Reviews in Clinical Laboratory Sciences 2008;43:69-101. [DOI: 10.1080/10408360500410407] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
117 Santos EA, Yoshida CF, Rolla VC, Mendes JM, Vieira IF, Arabe J, Gomes SA. Frequent occult hepatitis B virus infection in patients infected with human immunodeficiency virus type 1. Eur J Clin Microbiol Infect Dis 2003;22:92-8. [PMID: 12627282 DOI: 10.1007/s10096-002-0868-0] [Cited by in Crossref: 53] [Cited by in F6Publishing: 53] [Article Influence: 2.9] [Reference Citation Analysis]
118 Nishikawa H, Osaki Y. Clinical significance of occult hepatitis B infection in progression of liver disease and carcinogenesis. J Cancer 2013;4:473-80. [PMID: 23901347 DOI: 10.7150/jca.6609] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
119 Windyga J, Brojer E, Gronowska A, Grabarczyk P, Mikulska K, Szczepanik AB, Stefańska E, Buczma A. Preliminary results of HBV DNA testing of Polish haemophilia patients--lack of occult HBV infection. Haemophilia 2006;12:380-3. [PMID: 16834737 DOI: 10.1111/j.1365-2516.2006.01293.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
120 Rodríguez-iñigo E, Mariscal L, Bartolomé J, Castillo I, Navacerrada C, Ortiz-movilla N, Pardo M, Carreño V. Distribution of hepatitis B virus in the liver of chronic hepatitis C patients with occult hepatitis B virus infection: Liver Distribution of Occult HBV Infection. J Med Virol 2003;70:571-80. [DOI: 10.1002/jmv.10432] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 1.7] [Reference Citation Analysis]
121 Kwon OS, Jung YK, Bae KS, Kim JH, Kim SG, Kim YS, Lee JI, Lee JW, Kim YS. Anti-hepatitis B core positivity as a risk factor for hepatocellular carcinoma in alcoholic cirrhosis: a case-control study. Alcohol 2012;46:537-41. [PMID: 22572059 DOI: 10.1016/j.alcohol.2012.03.006] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
122 Vitale F, Tramuto F, Orlando A, Vizzini G, Meli V, Cerame G, Mazzucco W, Virdone R, Palazzo U, Villafrate MR. Can the serological status of anti-HBc alone be considered a sentinel marker for detection of occult HBV infection? J Med Virol. 2008;80:577-582. [PMID: 18297707 DOI: 10.1002/jmv.21121] [Cited by in Crossref: 43] [Cited by in F6Publishing: 41] [Article Influence: 3.3] [Reference Citation Analysis]
123 Elbahrawy A, Alaboudy A, El Moghazy W, Elwassief A, Alashker A, Abdallah AM. Occult hepatitis B virus infection in Egypt. World J Hepatol. 2015;7:1671-1678. [PMID: 26140086 DOI: 10.4254/wjh.v7.i12.1671] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
124 Toyoda H, Hayashi K, Murakami Y, Honda T, Katano Y, Nakano I, Goto H, Kumada T, Takamatsu J. Prevalence and clinical implications of occult hepatitis B viral infection in hemophilia patients in Japan. J Med Virol. 2004;73:195-199. [PMID: 15122792 DOI: 10.1002/jmv.20075] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 1.5] [Reference Citation Analysis]
125 Makuwa M, Souquière S, Telfer P, Apetrei C, Vray M, Bedjabaga I, Mouinga-ondeme A, Onanga R, Marx PA, Kazanji M, Roques P, Simon F. Identification of hepatitis B virus subgenotype A3 in rural Gabon. J Med Virol 2006;78:1175-84. [DOI: 10.1002/jmv.20678] [Cited by in Crossref: 37] [Cited by in F6Publishing: 40] [Article Influence: 2.5] [Reference Citation Analysis]
126 Choudhury D, Luna-Salazar C. Preventive health care in chronic kidney disease and end-stage renal disease. Nat Clin Pract Nephrol 2008;4:194-206. [PMID: 18285747 DOI: 10.1038/ncpneph0762] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
127 Roman S, Tanaka Y, Khan A, Kurbanov F, Kato H, Mizokami M, Panduro A. Occult hepatitis B in the genotype H-infected Nahuas and Huichol native Mexican population. J Med Virol. 2010;82:1527-1536. [PMID: 20648606 DOI: 10.1002/jmv.21846] [Cited by in Crossref: 38] [Cited by in F6Publishing: 39] [Article Influence: 3.5] [Reference Citation Analysis]
128 Caldwell S. Cryptogenic Cirrhosis: What Are We Missing? Curr Gastroenterol Rep 2010;12:40-8. [DOI: 10.1007/s11894-009-0082-7] [Cited by in Crossref: 24] [Cited by in F6Publishing: 16] [Article Influence: 2.2] [Reference Citation Analysis]
129 Caviglia GP, Abate ML, Manzini P, Danielle F, Ciancio A, Rosso C, Olivero A, Pellicano R, Touscoz GA, Smedile A, Rizzetto M. Occult hepatitis B virus infection in patients with chronic hepatitis C treated with antiviral therapy. Hepat Mon 2012;12:e7292. [PMID: 23300497 DOI: 10.5812/hepatmon.7292] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
130 Khorami F, Sobhani SA, Davoudian P, Khajeh E. Prevalence of HBc-Ab among HBs-Ag negative healthy blood donors in south of Iran. Electron Physician 2013;5:659-63. [PMID: 26120400 DOI: 10.14661/2013.659-663] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
131 Lok AS. Occult hepatitis B virus infection: diagnosis, implications and management? J Gastroenterol Hepatol 2004;19:S114-7. [DOI: 10.1111/j.1440-1746.2004.03657.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
132 Ganova-Raeva L, Punkova L, Campo DS, Dimitrova Z, Skums P, Vu NH, Dat do T, Dalton HR, Khudyakov Y. Cryptic Hepatitis B and E in Patients With Acute Hepatitis of Unknown Etiology. J Infect Dis 2015;212:1962-9. [PMID: 26155829 DOI: 10.1093/infdis/jiv315] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
133 Raffa G, Maimone S, Cargnel A, Santantonio T, Antonucci G, Massari M, Schiavini M, Caccamo G, Pollicino T, Raimondo G. Analysis of occult hepatitis B virus infection in liver tissue of HIV patients with chronic hepatitis C. AIDS 2007;21:2171-5. [PMID: 18090043 DOI: 10.1097/QAD.0b013e3282eea504] [Cited by in Crossref: 17] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
134 Colomina-rodríguez J, González-garcía D, Burgos-teruel A, Fernández-lorenz N, Guerrero-espejo A. Significado de la reactividad aislada anti-HBc como único marcador de infección de la hepatitis B. Enfermedades Infecciosas y Microbiología Clínica 2005;23:80-5. [DOI: 10.1157/13071611] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
135 Michalak TI, Mulrooney PM, Coffin CS. Low doses of hepadnavirus induce infection of the lymphatic system that does not engage the liver. J Virol. 2004;78:1730-1738. [PMID: 14747538 DOI: 10.1128/jvi.78.4.1730-1738.2004] [Cited by in Crossref: 74] [Cited by in F6Publishing: 29] [Article Influence: 4.4] [Reference Citation Analysis]
136 Chaudhuri V, Tayal R, Nayak B, Acharya SK, Panda SK. Occult hepatitis B virus infection in chronic liver disease: full-length genome and analysis of mutant surface promoter. Gastroenterology. 2004;127:1356-1371. [PMID: 15521005 DOI: 10.1053/j.gastro.2004.08.003] [Cited by in Crossref: 105] [Cited by in F6Publishing: 103] [Article Influence: 6.2] [Reference Citation Analysis]
137 Chen C. Time-dependent events in natural history of occult hepatitis B virus infection: the importance of population-based long-term follow-up study with repeated measurements. Journal of Hepatology 2005;42:438-40. [DOI: 10.1016/j.jhep.2005.01.003] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 1.1] [Reference Citation Analysis]
138 Hassan ZK, Hafez MM, Mansor TM, Zekri AR. Occult HBV infection among Egyptian hepatocellular carcinoma patients. Virol J. 2011;8:90. [PMID: 21371325 DOI: 10.1186/1743-422x-8-90] [Cited by in Crossref: 21] [Cited by in F6Publishing: 12] [Article Influence: 2.1] [Reference Citation Analysis]
139 Bani-Sadr F, Maillard A, Ponscarme D, Scieux C, Molina JM. Reactivation of HBV replication in HIV-HBV infected patients. Am J Med 2003;114:768-9. [PMID: 12829207 DOI: 10.1016/s0002-9343(03)00156-6] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
140 Ueda Y, Marusawa H, Ichinohe T, Kadowaki N, Uchiyama T, Chiba T. Effective treatment for de novo hepatitis B with nucleotide analogue in patients with hematological malignancies. Am J Hematol 2009;84:315-6. [PMID: 19350661 DOI: 10.1002/ajh.21388] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
141 Niederhauser C. Reducing the risk of hepatitis B virus transfusion-transmitted infection. J Blood Med 2011;2:91-102. [PMID: 22287868 DOI: 10.2147/JBM.S12899] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
142 Esmat G, El Kassas M, Hassany M, Gamil ME, El Raziky M. How to optimize HCV therapy in genotype 4 patients. Liver Int 2013;33:41-5. [DOI: 10.1111/liv.12059] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
143 Fang Y, Teng X, Xu WZ, Li D, Zhao HW, Fu LJ, Zhang FM, Gu HX. Molecular characterization and functional analysis of occult hepatitis B virus infection in Chinese patients infected with genotype C. J Med Virol. 2009;81:826-835. [PMID: 19319940 DOI: 10.1002/jmv.21463] [Cited by in Crossref: 35] [Cited by in F6Publishing: 36] [Article Influence: 2.9] [Reference Citation Analysis]
144 Gutiérrez-García ML, Fernandez-Rodriguez CM, Lledo-Navarro JL, Buhigas-Garcia I. Prevalence of occult hepatitis B virus infection. World J Gastroenterol. 2011;17:1538-1542. [PMID: 21472117 DOI: 10.3748/wjg.v17.i12.1538] [Cited by in CrossRef: 31] [Cited by in F6Publishing: 28] [Article Influence: 3.1] [Reference Citation Analysis]
145 Marcucci F, Mele A. Hepatitis viruses and non-Hodgkin lymphoma: epidemiology, mechanisms of tumorigenesis, and therapeutic opportunities. Blood. 2011;117:1792-1798. [PMID: 20959600 DOI: 10.1182/blood-2010-06-275818] [Cited by in Crossref: 163] [Cited by in F6Publishing: 137] [Article Influence: 14.8] [Reference Citation Analysis]
146 Schwartz JD, Llovet JM. Molecular Targeting in Hepatocellular Carcinoma. In: Kaufman HL, Wadler S, Antman K, editors. Molecular Targeting in Oncology. Totowa: Humana Press; 2008. pp. 165-210. [DOI: 10.1007/978-1-59745-337-0_8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
147 Aghakhani A, Banifazl M, Velayati AA, Eslamifar A, Ramezani A. Occult hepatitis B virus infection in hemodialysis patients: a concept for consideration. Ther Apher Dial. 2012;16:328-333. [PMID: 22817120 DOI: 10.1111/j.1744-9987.2012.01072.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
148 Tandoi F, Caviglia GP, Pittaluga F, Abate ML, Smedile A, Romagnoli R, Salizzoni M. Prediction of occult hepatitis B virus infection in liver transplant donors through hepatitis B virus blood markers. Digestive and Liver Disease 2014;46:1020-4. [DOI: 10.1016/j.dld.2014.07.172] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
149 Sengupta S, Rehman S, Durgapal H, Acharya SK, Panda SK. Role of surface promoter mutations in hepatitis B surface antigen production and secretion in occult hepatitis B virus infection. J Med Virol. 2007;79:220-228. [PMID: 17245717 DOI: 10.1002/jmv.20790] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 1.6] [Reference Citation Analysis]
150 Chu CJ, Lee SD. Occult hepatitis B virus infection in patients with chronic hepatitis C: An actor behind the scene or just a bystander? J Gastroenterol Hepatol 2010;25:221-3. [PMID: 20136983 DOI: 10.1111/j.1440-1746.2009.06134.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
151 Carpenter PA, Huang M, Mcdonald GB. Activation of occult hepatitis B from a seronegative patient after hematopoietic cell transplant: a cautionary tale. Blood 2002;99:4245-6. [DOI: 10.1182/blood-2001-12-0239] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 0.9] [Reference Citation Analysis]
152 Mrani S, Chemin I, Menouar K, Guillaud O, Pradat P, Borghi G, Trabaud MA, Chevallier P, Chevallier M, Zoulim F. Occult HBV infection may represent a major risk factor of non-response to antiviral therapy of chronic hepatitis C. J Med Virol. 2007;79:1075-1081. [PMID: 17596829 DOI: 10.1002/jmv.20943] [Cited by in Crossref: 62] [Cited by in F6Publishing: 62] [Article Influence: 4.4] [Reference Citation Analysis]
153 Hui C, Cheung WW, Leung K, Cheng VCC, Tang BSF, Li IWS, Luk JM, Lee NP, Kwong Y, Au W, Yuen K, Lau GK, Liang R. Retracted : Outcome and immune reconstitution of HBV-specific immunity in patients with reactivation of occult HBV infection after alemtuzumab-containing chemotherapy regimen. Hepatology 2008;48:NA-NA. [DOI: 10.1002/hep.22213] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
154 Kao JH, Chen PJ, Lai MY, Chen DS. Sequence analysis of pre-S/surface and pre-core/core promoter genes of hepatitis B virus in chronic hepatitis C patients with occult HBV infection. J Med Virol 2002;68:216-20. [PMID: 12210410 DOI: 10.1002/jmv.10188] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 1.8] [Reference Citation Analysis]
155 Bosch F, Ribes J, Díaz M, Cléries R. Primary liver cancer: Worldwide incidence and trends. Gastroenterology 2004;127:S5-S16. [DOI: 10.1053/j.gastro.2004.09.011] [Cited by in Crossref: 1676] [Cited by in F6Publishing: 1515] [Article Influence: 98.6] [Reference Citation Analysis]
156 Kao JH, Chen DS. Global control of hepatitis B virus infection. Lancet Infect Dis. 2002;2:395-403. [PMID: 12127351 DOI: 10.1016/s1473-3099(02)00315-8] [Cited by in Crossref: 555] [Cited by in F6Publishing: 190] [Article Influence: 29.2] [Reference Citation Analysis]
157 Obika M, Shinji T, Fujioka S, Terada R, Ryuko H, Lwin AA, Shiraha H, Koide N. Hepatitis B virus DNA in liver tissue and risk for hepatocarcinogenesis in patients with hepatitis C virus-related chronic liver disease. A prospective study. Intervirology. 2008;51:59-68. [PMID: 18349544 DOI: 10.1159/000121363] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 1.4] [Reference Citation Analysis]
158 Morrison BJ, Labo N, Miley WJ, Whitby D. Serodiagnosis for tumor viruses. Semin Oncol 2015;42:191-206. [PMID: 25843726 DOI: 10.1053/j.seminoncol.2014.12.024] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 3.7] [Reference Citation Analysis]
159 Batista SM, Andreasi MS, Borges AM, Lindenberg AS, Silva AL, Fernandes TD, Pereira EF, Basmage EA, Cardoso DD. Seropositivity for hepatitis B virus, vaccination coverage, and vaccine response in dentists from Campo Grande, Mato Grosso do Sul, Brazil. Mem Inst Oswaldo Cruz 2006;101:263-7. [DOI: 10.1590/s0074-02762006000300006] [Cited by in Crossref: 18] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
160 Adachi S, Shibuya A, Miura Y, Takeuchi A, Nakazawa T, Saigenji K. Impact of occult hepatitis B virus infection and prior hepatitis B virus infection on development of hepatocellular carcinoma in patients with liver cirrhosis due to hepatitis C virus. Scand J Gastroenterol. 2008;43:849-856. [PMID: 18584524 DOI: 10.1080/00365520801935459] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 2.5] [Reference Citation Analysis]
161 Fabrizi F, Messa PG, Lunghi G, Aucella F, Bisegna S, Mangano S, Villa M, Barbisoni F, Rusconi E, Martin P. Occult hepatitis B virus infection in dialysis patients: a multicentre survey. Aliment Pharmacol Ther 2005;21:1341-7. [PMID: 15932364 DOI: 10.1111/j.1365-2036.2005.02501.x] [Cited by in Crossref: 44] [Cited by in F6Publishing: 46] [Article Influence: 2.8] [Reference Citation Analysis]
162 Chenari M, Norouzi M, Ghalichi L, Rezaee A, Yari A, Alavian SM, Jazayeri SM. Characterization of overt and occult hepatitis B virus infection among HTLV-1 positive healthy carriers in the Northeast of Iran; AN HTLV-I endemic area. J Med Virol 2014;86:1861-7. [PMID: 25132488 DOI: 10.1002/jmv.24046] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
163 Marque-juillet S, Benghalia K, Monnier S, Fernand-laurent C, Mazeron M, Harzic M. Faut-il rechercher une hépatite B occulte chez les patients infectés par le virus de l’immunodéficience humaine (VIH) ? Pathologie Biologie 2010;58:e39-42. [DOI: 10.1016/j.patbio.2009.07.031] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
164 Nguyen VT, Law MG, Dore GJ. Hepatitis B-related hepatocellular carcinoma: epidemiological characteristics and disease burden. J Viral Hepat. 2009;16:453-463. [PMID: 19302335 DOI: 10.1111/j.1365-2893.2009.01117.x] [Cited by in Crossref: 185] [Cited by in F6Publishing: 194] [Article Influence: 15.4] [Reference Citation Analysis]
165 Motta JS, Mello FC, Lago BV, Perez RM, Gomes SA, Figueiredo FF. Occult hepatitis B virus infection and lamivudine-resistant mutations in isolates from renal patients undergoing hemodialysis. J Gastroenterol Hepatol. 2010;25:101-106. [PMID: 19817965 DOI: 10.1111/j.1440-1746.2009.05972.x] [Cited by in Crossref: 28] [Cited by in F6Publishing: 30] [Article Influence: 2.3] [Reference Citation Analysis]
166 Lee JJ, Kwon OS. [Occult hepatitis B virus infection and hepatocellular carcinoma]. Korean J Gastroenterol 2013;62:160-4. [PMID: 24077626 DOI: 10.4166/kjg.2013.62.3.160] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
167 Abdel-Maksoud NHM, El-Shamy A, Fawzy M, Gomaa HHA, Eltarabilli MMA. Hepatitis B variants among Egyptian patients undergoing hemodialysis. Microbiol Immunol 2019;63:77-84. [PMID: 30680771 DOI: 10.1111/1348-0421.12670] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
168 Yuen MF, Wong DK, Sablon E, Tse E, Ng IO, Yuan HJ, Siu CW, Sander TJ, Bourne EJ, Hall JG, Condreay LD, Lai CL. HBsAg seroclearance in chronic hepatitis B in the Chinese: virological, histological, and clinical aspects. Hepatology. 2004;39:1694-1701. [PMID: 15185311 DOI: 10.1002/hep.20240] [Cited by in Crossref: 175] [Cited by in F6Publishing: 155] [Article Influence: 10.3] [Reference Citation Analysis]
169 Tanaka H, Iwasaki Y, Nouso K, Kobayashi Y, Nakamura S, Matsumoto E, Toshikuni N, Kaneyoshi T, Ohsawa T, Takaguchi K, Fujio K, Senoh T, Ohnishi T, Sakaguchi K, Shiratori Y. Possible contribution of prior hepatitis B virus infection to the development of hepatocellular carcinoma. J Gastroenterol Hepatol 2005;20:850-6. [PMID: 15946131 DOI: 10.1111/j.1440-1746.2005.03823.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
170 Habibollahi P, Safari S, Daryani NE, Alavian SM. Occult hepatitis B infection and its possible impact on chronic hepatitis C virus infection. Saudi J Gastroenterol. 2009;15:220-224. [PMID: 19794265 DOI: 10.4103/1319-3767.56089] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
171 Lum PJ, Hahn JA, Shafer KP, Evans JL, Davidson PJ, Stein E, Moss AR. Hepatitis B virus infection and immunization status in a new generation of injection drug users in San Francisco. J Viral Hepat 2008;15:229-36. [PMID: 18233994 DOI: 10.1111/j.1365-2893.2007.00933.x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 1.9] [Reference Citation Analysis]
172 Ie SI, Turyadi, Sidarta E, Sadhewa A, Purnomo GA, Soedarmono YS, Pattiiha MZ, Thedja MD, Harahap AR, Muljono DH. High Prevalence of Hepatitis B Virus Infection in Young Adults in Ternate, Eastern Indonesia. Am J Trop Med Hyg 2015;93:1349-55. [PMID: 26392157 DOI: 10.4269/ajtmh.15-0331] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
173 Minuk GY, Kowalec K, Caouette S, Larke B, Osiowy C. The prevalence and long term outcome of occult hepatitis B virus infections in community based populations. J Med Virol 2012;84:1369-75. [PMID: 22825815 DOI: 10.1002/jmv.23351] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
174 Alavian SM, Miri SM, Hollinger FB, Jazayeri SM. Occult Hepatitis B (OBH) in Clinical Settings. Hepat Mon 2012;12:e6126. [PMID: 23087749 DOI: 10.5812/hepatmon.6126] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
175 Yang Z, Xu L, Liu L, Feng Q, Zhang L, Ma W, Saldanha J, Wang M, Zhao L. Routine screening of blood donations at Qingdao central blood bank, China, for hepatitis B virus (HBV) DNA with a real-time, multiplex nucleic acid test for HBV, hepatitis C virus, and human immunodeficiency virus Types 1 and 2: NAT screening of blood donors in China. Transfusion 2013;53:2538-44. [DOI: 10.1111/trf.12159] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
176 Ye X, Li T, Xu X, Du P, Zeng J, Zhu W, Yang B, Li C, Allain JP. Characterisation and follow-up study of occult hepatitis B virus infection in anti-HBc-positive qualified blood donors in southern China. Blood Transfus 2017;15:6-12. [PMID: 27416568 DOI: 10.2450/2016.0268-15] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
177 Javanmard D, Namaei MH, Farahmand M, Ziaee A, Amini E, Ziaee M. Molecular and serological characterization of occult hepatitis B virus infection among patients with hemophilia. J Med Virol 2019;91:1519-27. [PMID: 30908666 DOI: 10.1002/jmv.25470] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
178 Maheshwari A, Thuluvath PJ. Cryptogenic Cirrhosis and NAFLD: Are They Related? Am J Gastroenterology 2006;101:664-8. [DOI: 10.1111/j.1572-0241.2006.00478.x] [Cited by in Crossref: 61] [Cited by in F6Publishing: 45] [Article Influence: 4.1] [Reference Citation Analysis]
179 Kim SM, Lee KS, Park CJ, Lee JY, Kim KH, Park JY, Lee JH, Kim HY, Yoo JY, Jang MK. Prevalence of occult HBV infection among subjects with normal serum ALT levels in Korea. J Infect. 2007;54:185-191. [PMID: 16564573 DOI: 10.1016/j.jinf.2006.02.002] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 2.2] [Reference Citation Analysis]
180 Kanbay M, Gur G, Akcay A, Selcuk H, Yilmaz U, Arslan H, Boyacioglu S, Ozdemir FN. Is hepatitis C virus positivity a contributing factor to occult hepatitis B virus infection in hemodialysis patients? Dig Dis Sci 2006;51:1962-6. [PMID: 16977505 DOI: 10.1007/s10620-006-9421-9] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 1.5] [Reference Citation Analysis]
181 Bowden S. New directions in molecular diagnostics for hepatitis B: serum and tissue-based diagnostics. J Gastroenterol Hepatol 2004;19:S311-4. [DOI: 10.1111/j.1440-1746.2004.03694.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
182 Haushofer AC, Hauer R, Brunner H, Köller U, Trubert-exinger D, Halbmayer W, Koidl C, Kessler HH. No evidence of hepatitis B virus activity in patients with anti-HBc antibody positivity with or without anti-hepatitis C virus antibody positivity. Journal of Clinical Virology 2004;29:221-3. [DOI: 10.1016/s1386-6532(03)00156-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
183 Raimondo G, Pollicino T, Romanò L, Zanetti AR. A 2010 update on occult hepatitis B infection. Pathol Biol (Paris). 2010;58:254-257. [PMID: 20303674 DOI: 10.1016/j.patbio.2010.02.003] [Cited by in Crossref: 76] [Cited by in F6Publishing: 77] [Article Influence: 6.9] [Reference Citation Analysis]
184 Bessone F. Re-appraisal of old and new diagnostic tools in the current management of chronic hepatitis B. Liver Int. 2014;34:991-1000. [PMID: 25098191 DOI: 10.1111/liv.12499] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
185 Pogány K, Zaaijer HL, Prins JM, Wit FW, Lange JM, Beld MG. Occult hepatitis B virus infection before and 1 year after start of HAART in HIV type 1-positive patients. AIDS Res Hum Retroviruses. 2005;21:922-926. [PMID: 16386107 DOI: 10.1089/aid.2005.21.922] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 1.8] [Reference Citation Analysis]
186 Ferrari TC, Xavier MA, Vidigal PV, Amaral NS, Diniz PA, Resende AP, Miranda DM, Faria AC, Lima AS, Faria LC. Occult hepatitis B virus infection in liver transplant patients in a Brazilian referral center. Braz J Med Biol Res. 2014;47:990-994. [PMID: 25296362 DOI: 10.1590/1414-431x20143782] [Cited by in Crossref: 6] [Article Influence: 0.9] [Reference Citation Analysis]
187 Hudu SA, Harmal NS, Saeed MI, Alshrari AS, Malik YA, Niazlin MT, Hassan R, Sekawi Z. Molecular and serological detection of occult hepatitis B virus among healthy hepatitis B surface antigen-negative blood donors in Malaysia. Afr Health Sci 2016;16:677-83. [PMID: 27917199 DOI: 10.4314/ahs.v16i3.6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
188 Dény P, Zoulim F. Hepatitis B virus: from diagnosis to treatment. Pathol Biol (Paris). 2010;58:245-253. [PMID: 20580167 DOI: 10.1016/j.patbio.2010.05.002] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 2.6] [Reference Citation Analysis]
189 Cassini R, De Mitri MS, Gibellini D, Urbinati L, Bagaglio S, Morsica G, Domenicali M, Verucchi G, Bernardi M. A novel stop codon mutation within the hepatitis B surface gene is detected in the liver but not in the peripheral blood mononuclear cells of HIV-infected individuals with occult HBV infection. J Viral Hepat. 2013;20:42-49. [PMID: 23231083 DOI: 10.1111/j.1365-2893.2012.01623.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 1.8] [Reference Citation Analysis]
190 Raimondo G, Cacciamo G, Saitta C. Hepatitis B virus and hepatitis C virus co-infection: additive players in chronic liver disease? Annals of Hepatology 2005;4:100-6. [DOI: 10.1016/s1665-2681(19)32072-1] [Cited by in Crossref: 23] [Article Influence: 1.4] [Reference Citation Analysis]
191 Bart G, Piccolo P, Zhang L, Jacobson I, Schaefer RA, Kreek MJ. Markers for hepatitis A, B and C in methadone maintained patients: an unexpectedly high co-infection with silent hepatitis B. Addiction 2008;103:681-6. [PMID: 18339114 DOI: 10.1111/j.1360-0443.2008.02151.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
192 Miédougé M, Rostaing L, Mansuy JM, Sandres-sauné K, Boudet F, Izopet J. Screening for Hepatitis B Virus DNA in Serum of Organ Donors and Renal Transplant Recipients. Eur J Clin Microbiol Infect Dis 2003;22:246-8. [DOI: 10.1007/s10096-003-0889-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
193 O’Brien SF, Fearon MA, Yi QL, Fan W, Scalia V, Muntz IR, Vamvakas EC. Hepatitis B virus DNA-positive, hepatitis B surface antigen-negative blood donations intercepted by anti-hepatitis B core antigen testing: the Canadian Blood Services experience. Transfusion. 2007;47:1809-1815. [PMID: 17880605 DOI: 10.1111/j.1537-2995.2007.01396.x] [Cited by in Crossref: 38] [Cited by in F6Publishing: 38] [Article Influence: 2.7] [Reference Citation Analysis]
194 Hu K. Occult hepatitis B virus infection and its clinical implications. J Viral Hepat 2002;9:243-57. [DOI: 10.1046/j.1365-2893.2002.00344.x] [Cited by in Crossref: 204] [Cited by in F6Publishing: 198] [Article Influence: 10.7] [Reference Citation Analysis]
195 Neau D, Winnock M, Galpérine T, Jouvencel AC, Castéra L, Legrand E, Tranchant E, Balestre E, Lacoste D, Ragnaud JM, Dupon M, Lafon ME, Dabis F; Groupe d'Epidémiologie Clinique du SIDA en Aquitaine (GECSA). Isolated antibodies against the core antigen of hepatitis B virus in HIV-infected patients. HIV Med 2004;5:171-3. [PMID: 15139983 DOI: 10.1111/j.1468-1293.2004.00206.x] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 1.6] [Reference Citation Analysis]
196 Hamkar R, Aghakhani A, Soufian S, Banifazl M, Ghavami N, Nadri M, Sofian M, Ahmadi F, Razeghi E, Eslamifar A. Surface gene mutations of hepatitis B virus among high-risk patients with occult hepatitis B virus infection. Diagn Microbiol Infect Dis. 2010;66:285-291. [PMID: 19903586 DOI: 10.1016/j.diagmicrobio.2009.10.006] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.4] [Reference Citation Analysis]
197 Alhababi F, Sallam TA, Tong CY. The significance of 'anti-HBc only' in the clinical virology laboratory. J Clin Virol 2003;27:162-9. [PMID: 12829038 DOI: 10.1016/s1386-6532(02)00171-3] [Cited by in Crossref: 51] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
198 Yavuz BG, Pestana RC, Abugabal YI, Krishnan S, Chen J, Hassan MM, Wolff RA, Rashid A, Amin HM, Kaseb AO. Origin and role of hepatic myofibroblasts in hepatocellular carcinoma. Oncotarget 2020;11:1186-201. [PMID: 32284794 DOI: 10.18632/oncotarget.27532] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
199 Zöllner B, Feucht HH, Sterneck M, Schäfer H, Rogiers X, Fischer L. Clinical reactivation after liver transplantation with an unusual minor strain of hepatitis B virus in an occult carrier. Liver Transpl 2006;12:1283-9. [PMID: 16868945 DOI: 10.1002/lt.20858] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 0.7] [Reference Citation Analysis]
200 Motta-castro ARC, Martins RMB, Araujo NM, Niel C, Facholi GB, Lago BV, Mello FCA, Gomes SA. Molecular epidemiology of hepatitis B virus in an isolated Afro-Brazilian community. Arch Virol 2008;153:2197-205. [DOI: 10.1007/s00705-008-0237-0] [Cited by in Crossref: 39] [Cited by in F6Publishing: 37] [Article Influence: 3.0] [Reference Citation Analysis]
201 Reuben A. The crab, the turkey and a malignant tale from the year of the rooster. Hepatology 2005;41:944-50. [PMID: 15791605 DOI: 10.1002/hep.20674] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
202 Kwak MS, Kim YJ. Occult hepatitis B virus infection. World J Hepatol. 2014;6:860-869. [PMID: 25544873 DOI: 10.4254/wjh.v6.i12.860] [Cited by in Crossref: 44] [Cited by in F6Publishing: 39] [Article Influence: 6.3] [Reference Citation Analysis]
203 Coffin CS, Pham TN, Mulrooney PM, Churchill ND, Michalak TI. Persistence of isolated antibodies to woodchuck hepatitis virus core antigen is indicative of occult infection. Hepatology. 2004;40:1053-1061. [PMID: 15382154 DOI: 10.1002/hep.20419] [Cited by in Crossref: 19] [Cited by in F6Publishing: 29] [Article Influence: 1.1] [Reference Citation Analysis]
204 Pereira J, Gonçales N, Silva C, Lazarini M, Pavan M, Fais V, Gonçales Júnior F. HBV vaccination of HCV-infected patients with occult HBV infection and anti-HBc-positive blood donors. Braz J Med Biol Res 2006;39:525-31. [DOI: 10.1590/s0100-879x2006000400013] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
205 Sagnelli E, Pasquale G, Coppola N, Marrocco C, Scarano F, Imparato M, Sagnelli C, Scolastico C, Piccinino F. Liver histology in patients with HBsAg negative anti-HBc and anti-HCV positive chronic hepatitis. J Med Virol 2005;75:222-6. [DOI: 10.1002/jmv.20260] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 0.6] [Reference Citation Analysis]
206 Huang X, Hollinger FB. Occult hepatitis B virus infection and hepatocellular carcinoma: a systematic review. J Viral Hepat. 2014;21:153-162. [PMID: 24438677 DOI: 10.1111/jvh.12222] [Cited by in Crossref: 48] [Cited by in F6Publishing: 44] [Article Influence: 6.9] [Reference Citation Analysis]
207 Carmel R, Sarrai M. Diagnosis and management of clinical and subclinical cobalamin deficiency: advances and controversies. Curr Hematol Rep 2006;5:23-33. [PMID: 16537043 DOI: 10.1007/s11901-006-0019-7] [Cited by in Crossref: 12] [Cited by in F6Publishing: 20] [Article Influence: 0.8] [Reference Citation Analysis]
208 Wong P, Fung T, Mak S, Lo K, Tong GM, Wong Y, Loo C, Lam EK, Wong AK. Hepatitis B virus infection in dialysis patients. J Gastroenterol Hepatol 2005;20:1641-51. [DOI: 10.1111/j.1440-1746.2005.03837.x] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 2.1] [Reference Citation Analysis]
209 Fujiwara K, Tanaka Y, Orito E, Ohno T, Kato T, Sugauchi F, Suzuki S, Hattori Y, Sakurai M, Hasegawa I, Ozasa T, Kanie F, Kano H, Ueda R, Mizokami M. Lack of association between occult hepatitis B virus DNA viral load and aminotransferase levels in patients with hepatitis C virus-related chronic liver disease. J Gastroenterol Hepatol 2004;19:1343-7. [DOI: 10.1111/j.1440-1746.2004.03439.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 0.6] [Reference Citation Analysis]
210 El-Zaatari M, Kazma H, Naboulsi-Majzoub M, Haidar M, Ramlawi F, Mahfoud Z, Ramia S. Hepatitis B virus DNA in serum of 'anti-HBc only'-positive healthy Lebanese blood donors: significance and possible implications. J Hosp Infect 2007;66:278-82. [PMID: 17540476 DOI: 10.1016/j.jhin.2007.04.010] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.0] [Reference Citation Analysis]
211 Abaalkhail F, Elsiesy H, AlOmair A, Alghamdi MY, Alalwan A, AlMasri N, Al-Hamoudi W; Saudi Association for the Study of Liver Diseases and Transplantation (SASLT). SASLT practice guidelines for the management of hepatitis B virus. Saudi J Gastroenterol 2014;20:5-25. [PMID: 24496154 DOI: 10.4103/1319-3767.126311] [Cited by in Crossref: 13] [Cited by in F6Publishing: 18] [Article Influence: 1.9] [Reference Citation Analysis]
212 Makvandi M, Neisi N, Khalafkhany D, Makvandi K, Hajiani E, Shayesteh AA, Masjedi Zadeh A, Sina AH, Hamidifard M, Rasti M. Occult hepatitis B virus among the patients with abnormal alanine transaminase. Jundishapur J Microbiol. 2014;7:e11648. [PMID: 25485052 DOI: 10.5812/jjm.11648] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
213 Barros Júnior GM, Braga WS, Oliveira CM, Castilho Mda C, Araújo Jde R. [Occult hepatitis B: prevalence and clinical characteristics in a population with high endemicity of hepatitis B infection in the western Brazilian Amazon region]. Rev Soc Bras Med Trop 2008;41:596-601. [PMID: 19142439 DOI: 10.1590/s0037-86822008000600010] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
214 Lubel JS, Angus PW. Hepatitis B reactivation in patients receiving cytotoxic chemotherapy: diagnosis and management. J Gastroenterol Hepatol. 2010;25:864-871. [PMID: 20546439 DOI: 10.1111/j.1440-1746.2010.06243.x] [Cited by in Crossref: 56] [Cited by in F6Publishing: 52] [Article Influence: 5.1] [Reference Citation Analysis]
215 Koo YX, Tan DS, Tan IB, Quek R, Tao M, Lim ST. "Anti-HBc alone" in human immunodeficiency virus-positive and immuno-suppressed lymphoma patients. World J Gastroenterol 2009;15:3834-5. [PMID: 19673031 DOI: 10.3748/wjg.15.3834] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
216 Arababadi MK, Hassanshahi G, Pourfathollah AA, Zarandi ER, Kennedy D. Post-Transfusion Occult Hepatitis B (OBI): A Global Challenge for Blood Recipients and Health Authorities. Hepat Mon 2011;11:714-8. [DOI: 10.5812/kowsar.1735143x.505] [Cited by in Crossref: 7] [Article Influence: 0.7] [Reference Citation Analysis]
217 Datta S, Banerjee A, Chandra PK, Chakraborty S, Basu SK, Chakravarty R. Detection of a premature stop codon in the surface gene of hepatitis B virus from an HBsAg and antiHBc negative blood donor. J Clin Virol 2007;40:255-8. [PMID: 17869170 DOI: 10.1016/j.jcv.2007.08.003] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
218 Gao S, Duan ZP, Coffin CS. Clinical relevance of hepatitis B virus variants. World J Hepatol 2015;7:1086-96. [PMID: 26052397 DOI: 10.4254/wjh.v7.i8.1086] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 4.5] [Reference Citation Analysis]
219 Dreier J, Kroger M, Diekmann J, Gotting C, Kleesiek K. Intermittent HBV viraemia in an anti-HBc- and anti-HBs-positive blood donor. Transfus Med 2005;15:65-6. [DOI: 10.1111/j.1365-3148.2005.00553.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
220 Zanetti AR, Romanò L, Zappá A, Velati C. Changing patterns of hepatitis B infection in Italy and NAT testing for improving the safety of blood supply. Journal of Clinical Virology 2006;36:S51-5. [DOI: 10.1016/s1386-6532(06)80009-0] [Cited by in Crossref: 16] [Cited by in F6Publishing: 3] [Article Influence: 1.1] [Reference Citation Analysis]
221 Seeff LB. Sustained virologic response: is this equivalent to cure of chronic hepatitis C? Hepatology. 2013;57:438-440. [PMID: 22815252 DOI: 10.1002/hep.25964] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
222 Chen H, Su T, Tseng T, Yang W, Chen T, Chen P, Chen D, Kao J, Liu C. Impact of occult hepatitis B on the clinical outcomes of patients with chronic hepatitis C virus infection: A 10-year follow-up. Journal of the Formosan Medical Association 2017;116:697-704. [DOI: 10.1016/j.jfma.2016.11.002] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
223 Pondé RA. Atypical serological profiles in hepatitis B virus infection. Eur J Clin Microbiol Infect Dis 2013;32:461-76. [PMID: 23192489 DOI: 10.1007/s10096-012-1781-9] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
224 Taira R, Satake M, Momose S, Hino S, Suzuki Y, Murokawa H, Uchida S, Tadokoro K. Residual risk of transfusion-transmitted hepatitis B virus (HBV) infection caused by blood components derived from donors with occult HBV infection in Japan. Transfusion. 2013;53:1393-1404. [PMID: 23033944 DOI: 10.1111/j.1537-2995.2012.03909.x] [Cited by in Crossref: 61] [Cited by in F6Publishing: 52] [Article Influence: 6.8] [Reference Citation Analysis]
225 Rong G, Wang H, Bowlus CL, Wang C, Lu Y, Zeng Z, Qu J, Lou M, Chen Y, An L. Incidence and risk factors for hepatocellular carcinoma in primary biliary cirrhosis. Clin Rev Allergy Immunol. 2015;48:132-141. [PMID: 25762349 DOI: 10.1007/s12016-015-8483-x] [Cited by in Crossref: 34] [Cited by in F6Publishing: 26] [Article Influence: 6.8] [Reference Citation Analysis]
226 Soriano V, Miro JM, Garcia-samaniego J, Torre-cisneros J, Nunez M, del Romero J, Martin-carbonero L, Castilla J, Iribarren JA, Quereda C, Santin M, Gonzalez J, Arribas JR, Santos I, Hernandez-quero J, Ortega E, Asensi V, del Pozo MA, Berenguer J, Tural C, Clotet B, Leal M, Mallolas J, Sanchez-tapias JM, Moreno S, Gatell JM, Tellez MJ, Rubio R, Ledesma E, Domingo P, Barreiro P, Pedreira J, Romero M, Gonzalez-lahoz J, Lissen E. Consensus conference on chronic viral hepatitis and HIV infection: updated Spanish recommendations. J Viral Hepat 2004;11:2-17. [DOI: 10.1046/j.1365-2893.2003.00491.x] [Cited by in Crossref: 48] [Cited by in F6Publishing: 34] [Article Influence: 2.8] [Reference Citation Analysis]
227 Estevez J, Chen VL, Podlaha O, Li B, Le A, Vutien P, Chang ET, Rosenberg-Hasson Y, Jiang Z, Pflanz S, Ge D, Gaggar A, Nguyen MH. Differential Serum Cytokine Profiles in Patients with Chronic Hepatitis B, C, and Hepatocellular Carcinoma. Sci Rep 2017;7:11867. [PMID: 28928388 DOI: 10.1038/s41598-017-11975-7] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
228 Zhang Z, Zhang L, Dai Y, Jin L, Sun B, Su Q, Li X. Occult hepatitis B virus infection among people with a family history of chronic hepatitis B virus infection. J Med Virol. 2015;87:1890-1898. [PMID: 25964194 DOI: 10.1002/jmv.24245] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
229 Besisik F, Karaca C, Akyüz F, Horosanli S, Onel D, Badur S, Sever MS, Danalioglu A, Demir K, Kaymakoglu S. Occult HBV infection and YMDD variants in hemodialysis patients with chronic HCV infection. J Hepatol. 2003;38:506-510. [PMID: 12663244 DOI: 10.1016/s0168-8278(02)00457-9] [Cited by in Crossref: 57] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
230 Pollicino T, Saitta C. Occult hepatitis B virus and hepatocellular carcinoma. World J Gastroenterol. 2014;20:5951-5961. [PMID: 24876718 DOI: 10.3748/wjg.v20.i20.5951] [Cited by in CrossRef: 38] [Cited by in F6Publishing: 34] [Article Influence: 6.3] [Reference Citation Analysis]
231 Lai CL, Ratziu V, Yuen MF, Poynard T. Viral hepatitis B. Lancet. 2003;362:2089-2094. [PMID: 14697813 DOI: 10.1016/s0140-6736(03)15108-2] [Cited by in Crossref: 563] [Cited by in F6Publishing: 192] [Article Influence: 33.1] [Reference Citation Analysis]
232 Scotto G, Fazio V, Nicola C. Occult Hepatitis B Infection in Recent Immigrants to Italy: Occult B Infection in Immigrants. J Community Health 2020;45:357-62. [PMID: 31555924 DOI: 10.1007/s10900-019-00746-2] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
233 Kaech C, Pache I, Bürgisser P, Elzi L, Darling KE, Cavassini M. Immune response to hepatitis B vaccination in HIV-positive adults with isolated antibodies to HBV core antigen. J Infect 2012;65:157-64. [PMID: 22410383 DOI: 10.1016/j.jinf.2012.03.009] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.7] [Reference Citation Analysis]
234 Yokoyama K, Kumagai H, Takahashi M, Nagashima S, Okamoto H, Yamagata T. Occult hepatitis B virus infection in immunized children born to carrier mothers. Pediatr Int 2017;59:1010-6. [PMID: 28658511 DOI: 10.1111/ped.13352] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
235 Marrero JA, Lok AS. Occult hepatitis B virus infection in patients with hepatocellular carcinoma: Innocent bystander, cofactor, or culprit. Gastroenterology. 2004;126:347-350. [PMID: 14699513 DOI: 10.1053/j.gastro.2003.11.021] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 1.5] [Reference Citation Analysis]
236 Kremsdorf D, Soussan P, Paterlini-Brechot P, Brechot C. Hepatitis B virus-related hepatocellular carcinoma: paradigms for viral-related human carcinogenesis. Oncogene. 2006;25:3823-3833. [PMID: 16799624 DOI: 10.1038/sj.onc.1209559] [Cited by in Crossref: 203] [Cited by in F6Publishing: 186] [Article Influence: 13.5] [Reference Citation Analysis]
237 Opaleye OO, Oluremi AS, Atiba AB, Adewumi MO, Mabayoje OV, Donbraye E, Ojurongbe O, Olowe OA. Occult Hepatitis B Virus Infection among HIV Positive Patients in Nigeria. J Trop Med. 2014;2014:796121. [PMID: 24868208 DOI: 10.1155/2014/796121] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
238 Yeo W, Chan PK, Hui P, Ho WM, Lam KC, Kwan WH, Zhong S, Johnson PJ. Hepatitis B virus reactivation in breast cancer patients receiving cytotoxic chemotherapy: a prospective study. J Med Virol. 2003;70:553-561. [PMID: 12794717 DOI: 10.1002/jmv.10430] [Cited by in Crossref: 149] [Cited by in F6Publishing: 135] [Article Influence: 8.3] [Reference Citation Analysis]
239 Covolo L, Pollicino T, Raimondo G, Donato F. Occult hepatitis B virus and the risk for chronic liver disease: a meta-analysis. Dig Liver Dis. 2013;45:238-244. [PMID: 23146778 DOI: 10.1016/j.dld.2012.09.021] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 2.9] [Reference Citation Analysis]
240 Tanaka K. Does occult hepatitis B virus infection cause hepatocellular carcinoma in patients with chronic liver disease related to hepatitis C virus? Hepatology Research 2008;38:543-5. [DOI: 10.1111/j.1872-034x.2008.00350.x] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
241 Pitton MB, Kloeckner R, Herber S, Otto G, Kreitner KF, Dueber C. MRI versus 64-row MDCT for diagnosis of hepatocellular carcinoma. World J Gastroenterol 2009;15:6044-51. [PMID: 20027676 DOI: 10.3748/wjg.15.6044] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
242 Miura Y, Shibuya A, Adachi S, Takeuchi A, Tsuchihashi T, Nakazawa T, Saigenji K. Occult hepatitis B virus infection as a risk factor for hepatocellular carcinoma in patients with chronic hepatitis C in whom viral eradication fails. Hepatol Res. 2008;38:546-556. [PMID: 18179561 DOI: 10.1111/j.1872-034x.2007.00316.x] [Cited by in Crossref: 27] [Cited by in F6Publishing: 14] [Article Influence: 2.1] [Reference Citation Analysis]
243 Forner A, Hessheimer AJ, Isabel Real M, Bruix J. Treatment of hepatocellular carcinoma. Critical Reviews in Oncology/Hematology 2006;60:89-98. [DOI: 10.1016/j.critrevonc.2006.06.001] [Cited by in Crossref: 104] [Cited by in F6Publishing: 93] [Article Influence: 6.9] [Reference Citation Analysis]
244 Majzoobi MM, Mamani M, Hashemi SH, Gazan H, Ghasemibasir H, Nikbakht M, Esna-Ashari F. Isolated hepatitis B core antibody in HIV infected patients--can response to hepatitis B vaccine help to elucidate the cause? Caspian J Intern Med 2018;9:328-33. [PMID: 30510646 DOI: 10.22088/cjim.9.4.328] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
245 Bocharov G, Ludewig B, Bertoletti A, Klenerman P, Junt T, Krebs P, Luzyanina T, Fraser C, Anderson RM. Underwhelming the immune response: effect of slow virus growth on CD8+-T-lymphocyte responses. J Virol 2004;78:2247-54. [PMID: 14963121 DOI: 10.1128/jvi.78.5.2247-2254.2004] [Cited by in Crossref: 76] [Cited by in F6Publishing: 24] [Article Influence: 4.5] [Reference Citation Analysis]
246 Raimondo G, Navarra G, Mondello S, Costantino L, Colloredo G, Cucinotta E, Di Vita G, Scisca C, Squadrito G, Pollicino T. Occult hepatitis B virus in liver tissue of individuals without hepatic disease. J Hepatol. 2008;48:743-746. [PMID: 18314221 DOI: 10.1016/j.jhep.2008.01.023] [Cited by in Crossref: 129] [Cited by in F6Publishing: 129] [Article Influence: 9.9] [Reference Citation Analysis]
247 Kleinstern G, Seir RA, Perlman R, Abdeen Z, Khatib A, Elyan H, Dann EJ, Kedmi M, Ellis M, Nagler A, Amir G, Ben Yehuda D, Safadi R, Paltiel O. Associations between B-cell non-Hodgkin lymphoma and exposure, persistence and immune response to hepatitis B. Haematologica 2016;101:e303-5. [PMID: 27102500 DOI: 10.3324/haematol.2016.144840] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
248 Hernandez BY, Zhu X, Kwee S, Chan OT, Tsai N, Okimoto G, Horio D, McGlynn KA, Altekruse S, Wong LL. Viral hepatitis markers in liver tissue in relation to serostatus in hepatocellular carcinoma. Cancer Epidemiol Biomarkers Prev 2013;22:2016-23. [PMID: 23983238 DOI: 10.1158/1055-9965.EPI-13-0397] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
249 Sorà F, Ponziani FR, Laurenti L, Chiusolo P, Autore F, Gasbarrini A, Sica S, Pompili M. Low risk of hepatitis B virus reactivation in patients with resolved infection and chronic myeloid leukemia treated with tyrosine kinase inhibitors. Leukemia & Lymphoma 2016;58:993-5. [DOI: 10.1080/10428194.2016.1219906] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
250 Wei XL, Qiu MZ, Jin Y, Huang YX, Wang RY, Chen WW, Wang DS, Wang F, Luo HY, Zhang DS, Wang FH, Li YH, Xu RH. Hepatitis B virus infection is associated with gastric cancer in China: an endemic area of both diseases. Br J Cancer 2015;112:1283-90. [PMID: 25695484 DOI: 10.1038/bjc.2014.406] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 5.3] [Reference Citation Analysis]
251 Bosch FX, Ribes J, Cléries R, Díaz M. Epidemiology of Hepatocellular Carcinoma. Clinics in Liver Disease 2005;9:191-211. [DOI: 10.1016/j.cld.2004.12.009] [Cited by in Crossref: 601] [Cited by in F6Publishing: 532] [Article Influence: 37.6] [Reference Citation Analysis]
252 Sucupira MV, Mello FC, Santos EA, Niel C, Rolla VC, Arabe J, Gomes SA. Patterns of hepatitis B virus infection in Brazilian human immunodeficiency virus infected patients: high prevalence of occult infection and low frequency of lamivudine resistant mutations. Mem Inst Oswaldo Cruz. 2006;101:655-660. [PMID: 17072479 DOI: 10.1590/s0074-02762006000600013] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
253 Núñez M, Ríos P, Pérez-Olmeda M, Soriano V. Lack of 'occult' hepatitis B virus infection in HIV-infected patients. AIDS 2002;16:2099-101. [PMID: 12370518 DOI: 10.1097/00002030-200210180-00024] [Cited by in Crossref: 60] [Cited by in F6Publishing: 63] [Article Influence: 3.2] [Reference Citation Analysis]
254 Kudo A, Tanaka S, Ban D, Matsumura S, Irie T, Ochiai T, Nakamura N, Arii S, Tanabe M. Alcohol consumption and recurrence of non-B or non-C hepatocellular carcinoma after hepatectomy: a propensity score analysis. J Gastroenterol. 2014;49:1352-1361. [PMID: 24136219 DOI: 10.1007/s00535-013-0899-6] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
255 Torres-baranda R, Bastidas-ramírez BE, Maldonado-gonzález M, Sánchez-orozco LV, Vázquez-vals E, Rodríguez-noriega E, Panduro A. Occult hepatitis B in mexican patients with HIV, an analysis using nested polymerase chain reaction. Annals of Hepatology 2006;5:34-40. [DOI: 10.1016/s1665-2681(19)32037-x] [Cited by in Crossref: 17] [Article Influence: 1.1] [Reference Citation Analysis]
256 Shaw T, Bowden S, Locarnini S. Chemotherapy for hepatitis B: new treatment options necessitate reappraisal of traditional endpoints. Gastroenterology. 2002;123:2135-2140. [PMID: 12454868 DOI: 10.1053/gast.2002.37288] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 0.7] [Reference Citation Analysis]
257 Shibolet O, Ilan Y, Gillis S, Hubert A, Shouval D, Safadi R. Lamivudine therapy for prevention of immunosuppressive-induced hepatitis B virus reactivation in hepatitis B surface antigen carriers. Blood. 2002;100:391-396. [PMID: 12091327 DOI: 10.1182/blood.v100.2.391] [Cited by in Crossref: 116] [Cited by in F6Publishing: 26] [Article Influence: 6.1] [Reference Citation Analysis]
258 Rendon JC, Cortes-Mancera F, Restrepo-Gutierrez JC, Hoyos S, Navas MC. Molecular characterization of occult hepatitis B virus infection in patients with end-stage liver disease in Colombia. PLoS One 2017;12:e0180447. [PMID: 28686707 DOI: 10.1371/journal.pone.0180447] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
259 Hollinger FB. Hepatitis B virus infection and transfusion medicine: science and the occult. Transfusion. 2008;48:1001-1026. [PMID: 18454738 DOI: 10.1111/j.1537-2995.2008.01701.x] [Cited by in Crossref: 119] [Cited by in F6Publishing: 108] [Article Influence: 9.2] [Reference Citation Analysis]
260 Villanueva A, Toffanin S, Llovet JM. Linking molecular classification of hepatocellular carcinoma and personalized medicine: preliminary steps. Curr Opin Oncol. 2008;20:444-453. [PMID: 18525342 DOI: 10.1097/CCO.0b013e328302c9e9] [Cited by in Crossref: 52] [Cited by in F6Publishing: 19] [Article Influence: 4.0] [Reference Citation Analysis]
261 El-sherif A, Abou-shady M, Abou-zeid H, Elwassief A, Elbahrawy A, Ueda Y, Chiba T, Hosney A. Antibody to hepatitis B core antigen as a screening test for occult hepatitis B virus infection in Egyptian chronic hepatitis C patients. J Gastroenterol 2009;44:359-64. [DOI: 10.1007/s00535-009-0020-3] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 1.8] [Reference Citation Analysis]
262 Galy O, Chemin I, Le Roux E, Villar S, Le Calvez-Kelm F, Lereau M, Gouas D, Vieco B, Suarez I, Navas MC. Mutations in TP53 and CTNNB1 in Relation to Hepatitis B and C Infections in Hepatocellular Carcinomas from Thailand. Hepat Res Treat. 2011;2011:697162. [PMID: 21760996 DOI: 10.1155/2011/697162] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
263 Allice T, Cerutti F, Pittaluga F, Varetto S, Gabella S, Marzano A, Franchello A, Colucci G, Ghisetti V. COBAS AmpliPrep-COBAS TaqMan hepatitis B virus (HBV) test: a novel automated real-time PCR assay for quantification of HBV DNA in plasma. J Clin Microbiol. 2007;45:828-834. [PMID: 17229858 DOI: 10.1128/jcm.00914-06] [Cited by in Crossref: 45] [Cited by in F6Publishing: 17] [Article Influence: 3.2] [Reference Citation Analysis]
264 Yoneda M, Fujita K, Nozaki Y, Endo H, Takahashi H, Hosono K, Suzuki K, Mawatari H, Kirikoshi H, Inamori M. Efficacy of ezetimibe for the treatment of non-alcoholic steatohepatitis: An open-label, pilot study. Hepatol Res. 2010;40:566-573. [PMID: 20412324 DOI: 10.1111/j.1872-034x.2010.00664.x] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
265 Branco F, Mattos AA, Coral GP, Vanderborght B, Santos DE, França P, Alexandre C. Occult hepatitis B virus infection in patients with chronic liver disease due to hepatitis C virus and hepatocellular carcinoma in Brazil. Arq Gastroenterol 2007;44:58-63. [PMID: 17639185 DOI: 10.1590/s0004-28032007000100013] [Cited by in Crossref: 19] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
266 Busch MP. Should HBV DNA NAT replace HBsAg and/or anti-HBc screening of blood donors? Transfusion Clinique et Biologique 2004;11:26-32. [DOI: 10.1016/j.tracli.2003.12.003] [Cited by in Crossref: 63] [Cited by in F6Publishing: 62] [Article Influence: 3.7] [Reference Citation Analysis]
267 Rossi D, Sala L, Minisini R, Fabris C, Falleti E, Cerri M, Burlone ME, Toniutto P, Gaidano G, Pirisi M. Occult hepatitis B virus infection of peripheral blood mononuclear cells among treatment-naive patients with chronic lymphocytic leukemia. Leuk Lymphoma. 2009;50:604-611. [PMID: 19373659 DOI: 10.1080/10428190902777673] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 1.7] [Reference Citation Analysis]
268 Lusida MI, Juniastuti, Yano Y. Current hepatitis B virus infection situation in Indonesia and its genetic diversity. World J Gastroenterol 2016;22:7264-74. [PMID: 27621573 DOI: 10.3748/wjg.v22.i32.7264] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
269 Wang J, He Y, Jin D, Liu J, Zheng J, Yuan N, Bai Y, Yan T, Yang Y, Liu Y, Zhang S, Zhao Y, Chen T. No response to hepatitis B vaccine in infants born to HBsAg(+) mothers is associated to the transplacental transfer of HBsAg. Infect Dis (Lond) 2017;49:576-83. [PMID: 28276802 DOI: 10.1080/23744235.2017.1292541] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
270 de la Fuente RA, Gutiérrez ML, Garcia-Samaniego J, Fernández-Rodriguez C, Lledó JL, Castellano G. Pathogenesis of occult chronic hepatitis B virus infection. World J Gastroenterol. 2011;17:1543-1548. [PMID: 21472118 DOI: 10.3748/wjg.v17.i12.1543] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 19] [Article Influence: 1.7] [Reference Citation Analysis]
271 Hou J, Liu Z, Gu F. Epidemiology and Prevention of Hepatitis B Virus Infection. Int J Med Sci 2005;2:50-7. [PMID: 15968340 DOI: 10.7150/ijms.2.50] [Cited by in Crossref: 164] [Cited by in F6Publishing: 157] [Article Influence: 10.3] [Reference Citation Analysis]
272 Kim KH, Chang HY, Park JY, Park ES, Park YK, Han KH, Ahn SH. Spontaneous HBsAg loss in Korean patients: relevance of viral genotypes, S gene mutations, and covalently closed circular DNA copy numbers. Clin Mol Hepatol. 2014;20:251-260. [PMID: 25320728 DOI: 10.3350/cmh.2014.20.3.251] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
273 Liu C, Chen D, Chen P. Epidemiology of HBV infection in Asian blood donors: Emphasis on occult HBV infection and the role of NAT. Journal of Clinical Virology 2006;36:S33-44. [DOI: 10.1016/s1386-6532(06)80007-7] [Cited by in Crossref: 72] [Cited by in F6Publishing: 24] [Article Influence: 4.8] [Reference Citation Analysis]
274 Sofian M, Aghakhani A, Banifazl M, Azadmanesh K, Farazi AA, McFarland W, Eslamifar A, Ramezani A. Viral hepatitis and HIV infection among injection drug users in a central Iranian City. J Addict Med 2012;6:292-6. [PMID: 22895463 DOI: 10.1097/ADM.0b013e3182659928] [Cited by in Crossref: 22] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
275 Ott JJ, Stevens GA, Groeger J, Wiersma ST. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine. 2012;30:2212-2219. [PMID: 22273662 DOI: 10.1016/j.vaccine.2011.12.116] [Cited by in Crossref: 1111] [Cited by in F6Publishing: 1026] [Article Influence: 123.4] [Reference Citation Analysis]
276 Oluyinka OO, Tong HV, Bui Tien S, Fagbami AH, Adekanle O, Ojurongbe O, Bock CT, Kremsner PG, Velavan TP. Occult Hepatitis B Virus Infection in Nigerian Blood Donors and Hepatitis B Virus Transmission Risks. PLoS One. 2016;10:e0131912. [PMID: 26148052 DOI: 10.1371/journal.pone.0131912] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 4.3] [Reference Citation Analysis]
277 Dufour DR. Hepatitis B surface antigen (HBsAg) assays--are they good enough for their current uses? Clin Chem 2006;52:1457-9. [PMID: 16873296 DOI: 10.1373/clinchem.2006.072504] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
278 Zhang M, Gong Y, Osiowy C, Minuk GY. Rapid detection of hepatitis B virus mutations using real-time PCR and melting curve analysis. Hepatology. 2002;36:723-728. [PMID: 12198666 DOI: 10.1053/jhep.2002.35346] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 1.6] [Reference Citation Analysis]
279 Kim EB, Kim DS, Park SJ, Park Y, Rho KH, Kim SJ. Hepatitis B virus reactivation in a surface antigen-negative and antibody-positive patient after rituximab plus CHOP chemotherapy. Cancer Res Treat 2008;40:36-8. [PMID: 19688064 DOI: 10.4143/crt.2008.40.1.36] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
280 Kitab B, Ezzikouri S, Alaoui R, Nadir S, Badre W, Trepo C, Chemin I, Benjelloun S. Occult HBV infection in Morocco: from chronic hepatitis to hepatocellular carcinoma. Liver Int. 2014;34:e144-e150. [PMID: 24502524 DOI: 10.1111/liv.12482] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.9] [Reference Citation Analysis]
281 Keeffe EB, Dieterich DT, Han SH, Jacobson IM, Martin P, Schiff ER, Tobias H, Wright TL. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States. Clin Gastroenterol Hepatol. 2004;2:87-106. [PMID: 15017613 DOI: 10.1016/s1542-3565(03)00312-4] [Cited by in Crossref: 153] [Cited by in F6Publishing: 32] [Article Influence: 9.0] [Reference Citation Analysis]
282 Liu F, Wang XW, Chen L, Hu P, Ren H, Hu HD. Systematic review with meta-analysis: development of hepatocellular carcinoma in chronic hepatitis B patients with hepatitis B surface antigen seroclearance. Aliment Pharmacol Ther. 2016;43:1253-1261. [PMID: 27117732 DOI: 10.1111/apt.13634] [Cited by in Crossref: 41] [Cited by in F6Publishing: 35] [Article Influence: 8.2] [Reference Citation Analysis]
283 Shire AM, Roberts LR. Occult hepatitis B virus infection: bit player or role player? Hepatology. 2011;54:760-763. [PMID: 21735471 DOI: 10.1002/hep.24528] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
284 Sav T, Gursoy S, Torun E, Sav NM, Unal A, Oymak O, Utas C. Occult HBV infection in continuous ambulatory peritoneal dialysis and hemodialysis patients. Ren Fail 2010;32:74-7. [PMID: 20113270 DOI: 10.3109/08860220903391242] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
285 Togashi H, Hashimoto C, Yokozawa J, Suzuki A, Sugahara K, Saito T, Yamaguchi I, Badawi H, Kainuma N, Aoyama M, Ohya H, Akatsuka T, Tanaka Y, Mizokami M, Kawata S. What can be revealed by extending the sensitivity of HBsAg detection to below the present limit? J Hepatol 2008;49:17-24. [PMID: 18479773 DOI: 10.1016/j.jhep.2008.03.019] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
286 Maldonado-Rodriguez A, Cevallos AM, Rojas-Montes O, Enriquez-Navarro K, Alvarez-Muñoz MT, Lira R. Occult hepatitis B virus co-infection in human immunodeficiency virus-positive patients: A review of prevalence, diagnosis and clinical significance. World J Hepatol 2015;7:253-60. [PMID: 25729480 DOI: 10.4254/wjh.v7.i2.253] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
287 Mulrooney-Cousins PM, Michalak TI. Persistent occult hepatitis B virus infection: experimental findings and clinical implications. World J Gastroenterol. 2007;13:5682-5686. [PMID: 17963292 DOI: 10.3748/wjg.v13.i43.5682] [Cited by in CrossRef: 48] [Cited by in F6Publishing: 47] [Article Influence: 3.7] [Reference Citation Analysis]
288 de Franchis R, Hadengue A, Lau G, Lavanchy D, Lok A, McIntyre N, Mele A, Paumgartner G, Pietrangelo A, Rodés J. EASL International Consensus Conference on Hepatitis B. 13-14 September, 2002 Geneva, Switzerland. Consensus statement (long version). J Hepatol. 2003;39 Suppl 1:S3-25. [PMID: 14708673 DOI: 10.1016/s0168-8278(03)00378-7] [Cited by in Crossref: 59] [Article Influence: 3.5] [Reference Citation Analysis]
289 Mak LY, Wong DK, Cheung KS, Seto WK, Lai CL, Yuen MF. Review article: hepatitis B core-related antigen (HBcrAg): an emerging marker for chronic hepatitis B virus infection. Aliment Pharmacol Ther. 2018;47:43-54. [PMID: 29035003 DOI: 10.1111/apt.14376] [Cited by in Crossref: 80] [Cited by in F6Publishing: 70] [Article Influence: 20.0] [Reference Citation Analysis]
290 Hu Y, Grau LE, Scott G, Seal KH, Marshall PA, Singer M, Heimer R. Economic evaluation of delivering hepatitis B vaccine to injection drug users. Am J Prev Med 2008;35:25-32. [PMID: 18541174 DOI: 10.1016/j.amepre.2008.03.028] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 2.1] [Reference Citation Analysis]
291 Li D, Gao G, Jiang H, Tang Z, Yu Y, Zang G. Hepatitis B virus-associated glomerulonephritis in HBsAg serological-negative patients. Eur J Gastroenterol Hepatol 2015;27:65-9. [PMID: 25386761 DOI: 10.1097/MEG.0000000000000236] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
292 Umeda M, Marusawa H, Ueda M, Takada Y, Egawa H, Uemoto S, Chiba T. Beneficial effects of short-term lamivudine treatment for de novo hepatitis B virus reactivation after liver transplantation. Am J Transplant 2006;6:2680-5. [PMID: 17049057 DOI: 10.1111/j.1600-6143.2006.01542.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
293 Wu SS, Shan QY, Xie WX, Chen B, Huang Y, Guo Y, Xie XY, Lu MD, Peng BG, Kuang M, Shen SL, Wang W. Outcomes after hepatectomy of patients with positive HBcAb Non-B Non-C hepatocellular carcinoma compared to overt hepatitis B virus hepatocellular carcinoma. Clin Transl Oncol 2020;22:401-10. [PMID: 31172445 DOI: 10.1007/s12094-019-02141-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
294 Jeantet D, Chemin I, Mandrand B, Zoulim F, Trepo C, Kay A. Characterization of two hepatitis B virus populations isolated from a hepatitis B surface antigen-negative patient. Hepatology. 2002;35:1215-1224. [PMID: 11981772 DOI: 10.1053/jhep.2002.32710] [Cited by in Crossref: 45] [Cited by in F6Publishing: 44] [Article Influence: 2.4] [Reference Citation Analysis]
295 Fontana R. Are we ready for marginal hepatitis B core antibody-positive living liver donors? Liver Transplantation 2003;9:833-6. [DOI: 10.1053/jlts.2003.50141] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
296 Ramezani A, Aghasadeghi MR, Ahmadi F, Razeghi E, Eslamifar A, Banifazl M, Sofian M, Bahramali G, Hekmat S, Aghakhani A. Isolated anti-hbc and occult HBV infection in dialysis patients. Nephrourol Mon. 2015;7:e22674. [PMID: 25738121 DOI: 10.5812/numonthly.22674] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.1] [Reference Citation Analysis]
297 Coppola N, Gentile I, Pasquale G, Buonomo AR, Capoluongo N, D’armiento M, Borgia G, Sagnelli E. Anti-HBc positivity was associated with histological cirrhosis in patients with chronic hepatitis C. Annals of Hepatology 2014;13:20-6. [DOI: 10.1016/s1665-2681(19)30900-7] [Cited by in Crossref: 20] [Article Influence: 2.9] [Reference Citation Analysis]
298 Umeda M, Marusawa H, Seno H, Katsurada A, Nabeshima M, Egawa H, Uemoto S, Inomata Y, Tanaka K, Chiba T. Hepatitis B virus infection in lymphatic tissues in inactive hepatitis B carriers. J Hepatol. 2005;42:806-812. [PMID: 15885350 DOI: 10.1016/j.jhep.2005.01.016] [Cited by in Crossref: 47] [Cited by in F6Publishing: 40] [Article Influence: 2.9] [Reference Citation Analysis]
299 Hui CK, Lie A, Au WY, Leung YH, Ma SY, Cheung WW, Zhang HY, Chim CS, Kwong YL, Liang R, Lau GK. A long-term follow-up study on hepatitis B surface antigen-positive patients undergoing allogeneic hematopoietic stem cell transplantation. Blood 2005;106:464-9. [PMID: 15797991 DOI: 10.1182/blood-2005-02-0698] [Cited by in Crossref: 61] [Cited by in F6Publishing: 54] [Article Influence: 3.8] [Reference Citation Analysis]
300 Elghannam DM, Aly RM, Goda EF, Eltoraby EE, Farag RE. Clinical significance of antibody to hepatitis B core antigen in multitransfused hemodialysis patients. Asian J Transfus Sci 2009;3:14-7. [PMID: 20041091 DOI: 10.4103/0973-6247.45256] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
301 Drosten C, Nippraschk T, Manegold C, Meisel H, Brixner V, Roth W, Apedjinou A, Günther S. Prevalence of hepatitis B virus DNA in anti-HBc-positive/HBsAg-negative sera correlates with HCV but not HIV serostatus. Journal of Clinical Virology 2004;29:59-68. [DOI: 10.1016/s1386-6532(03)00090-8] [Cited by in Crossref: 15] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
302 Knöll A, Pietrzyk M, Loss M, Goetz WA, Jilg W. Solid-organ transplantation in HBsAg-negative patients with antibodies to HBV core antigen: low risk of HBV reactivation. Transplantation. 2005;79:1631-1633. [PMID: 15940056 DOI: 10.1097/01.tp.0000163468.80223.74] [Cited by in Crossref: 52] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
303 Xie M, Rao W, Yang T, Deng Y, Zheng H, Pan C, Liu Y, Shen Z, Jia J. Occult hepatitis B virus infection predicts de novo hepatitis B infection in patients with alcoholic cirrhosis after liver transplantation. Liver Int. 2015;35:897-904. [PMID: 24750566 DOI: 10.1111/liv.12567] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
304 Coffin CS, Mulrooney-Cousins PM, Lee SS, Michalak TI, Swain MG. Profound suppression of chronic hepatitis C following superinfection with hepatitis B virus. Liver Int. 2007;27:722-726. [PMID: 17498260 DOI: 10.1111/j.1478-3231.2007.01477.x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 1.4] [Reference Citation Analysis]
305 Sarin SK, Kumar M, Lau GK, Abbas Z, Chan HL, Chen CJ, Chen DS, Chen HL, Chen PJ, Chien RN, Dokmeci AK, Gane E, Hou JL, Jafri W, Jia J, Kim JH, Lai CL, Lee HC, Lim SG, Liu CJ, Locarnini S, Al Mahtab M, Mohamed R, Omata M, Park J, Piratvisuth T, Sharma BC, Sollano J, Wang FS, Wei L, Yuen MF, Zheng SS, Kao JH. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int. 2016;10:1-98. [PMID: 26563120 DOI: 10.1007/s12072-015-9675-4] [Cited by in Crossref: 1076] [Cited by in F6Publishing: 949] [Article Influence: 179.3] [Reference Citation Analysis]
306 Dufour DR. Liver Disease. Tietz Textbook of Clinical Chemistry and Molecular Diagnostics. Elsevier; 2012. pp. 1637-93. [DOI: 10.1016/b978-1-4160-6164-9.00050-0] [Cited by in Crossref: 3] [Article Influence: 0.3] [Reference Citation Analysis]
307 Toyoda H, Kumada T, Kiriyama S, Sone Y, Tanikawa M, Hisanaga Y, Kanamori A, Yamaguchi A, Isogai M, Kaneoka Y, Washizu J. Characteristics and prognosis of patients in Japan with viral marker-negative hepatocellular carcinoma. J Gastroenterol Hepatol 2008;23:459-66. [PMID: 17854425 DOI: 10.1111/j.1440-1746.2007.05138.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
308 Felício AC, Fukujima MM, Fiorot Jr JA, Prado GFD, Carvalho Filho RJD, Rodrigues CA, Morelli VM, Lourenço DM. Cerebral venous thrombosis and hepatitis: case report. Arq Neuro-Psiquiatr 2006;64:1041-2. [DOI: 10.1590/s0004-282x2006000600033] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
309 Raimondo G, Pollicino T, Cacciola I, Squadrito G. Occult hepatitis B virus infection. J Hepatol. 2007;46:160-170. [PMID: 17112622 DOI: 10.1016/j.jhep.2006.10.007] [Cited by in Crossref: 335] [Cited by in F6Publishing: 318] [Article Influence: 22.3] [Reference Citation Analysis]
310 Yoshikawa A, Gotanda Y, Itabashi M, Minegishi K, Kanemitsu K, Nishioka K; the Japanese Red Cross NAT Screening Research Group. Hepatitis B NAT virus-positive blood donors in the early and late stages of HBV infection: analyses of the window period and kinetics of HBV DNA. Vox Sang 2005;88:77-86. [DOI: 10.1111/j.1423-0410.2005.00602.x] [Cited by in Crossref: 60] [Cited by in F6Publishing: 58] [Article Influence: 3.8] [Reference Citation Analysis]
311 Minuk GY, Sun DF, Greenberg R, Zhang M, Hawkins K, Uhanova J, Gutkin A, Bernstein K, Giulivi A, Osiowy C. Occult hepatitis B virus infection in a North American adult hemodialysis patient population. Hepatology. 2004;40:1072-1077. [PMID: 15486926 DOI: 10.1002/hep.20435] [Cited by in Crossref: 94] [Cited by in F6Publishing: 86] [Article Influence: 5.5] [Reference Citation Analysis]
312 Coppola N, Onorato L, Pisaturo M, Macera M, Sagnelli C, Martini S, Sagnelli E. Role of occult hepatitis B virus infection in chronic hepatitis C. World J Gastroenterol. 2015;21:11931-11940. [PMID: 26576082 DOI: 10.3748/wjg.v21.i42.11931] [Cited by in CrossRef: 27] [Cited by in F6Publishing: 23] [Article Influence: 5.4] [Reference Citation Analysis]
313 Torbenson M, Thomas DL. Occult hepatitis B. Lancet Infect Dis. 2002;2:479-486. [PMID: 12150847 DOI: 10.1016/s1473-3099(02)00345-6] [Cited by in Crossref: 360] [Cited by in F6Publishing: 128] [Article Influence: 18.9] [Reference Citation Analysis]
314 Hui C, Sun J, Au W, Lie AK, Yueng Y, Zhang H, Lee NP, Hou J, Liang R, Lau GK. Occult hepatitis B virus infection in hematopoietic stem cell donors in a hepatitis B virus endemic area. Journal of Hepatology 2005;42:813-9. [DOI: 10.1016/j.jhep.2005.01.018] [Cited by in Crossref: 69] [Cited by in F6Publishing: 62] [Article Influence: 4.3] [Reference Citation Analysis]
315 Liu Y, Li P, Li C, Zhou J, Wu C, Zhou YH. Detection of hepatitis B virus DNA among accepted blood donors in Nanjing, China. Virol J. 2010;7:193. [PMID: 20718994 DOI: 10.1186/1743-422x-7-193] [Cited by in Crossref: 22] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
316 Khattab E, Chemin I, Vuillermoz I, Vieux C, Mrani S, Guillaud O, Trepo C, Zoulim F. Analysis of HCV co-infection with occult hepatitis B virus in patients undergoing IFN therapy. J Clin Virol. 2005;33:150-157. [PMID: 15911431 DOI: 10.1016/j.jcv.2004.10.016] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 1.4] [Reference Citation Analysis]
317 Bréchot C. Pathogenesis of hepatitis B virus—related hepatocellular carcinoma: Old and new paradigms. Gastroenterology 2004;127:S56-61. [DOI: 10.1053/j.gastro.2004.09.016] [Cited by in Crossref: 310] [Cited by in F6Publishing: 282] [Article Influence: 18.2] [Reference Citation Analysis]
318 Sagnelli E, Pisaturo M, Martini S, Filippini P, Sagnelli C, Coppola N. Clinical impact of occult hepatitis B virus infection in immunosuppressed patients. World J Hepatol. 2014;6:384-393. [PMID: 25018849 DOI: 10.4254/wjh.v6.i6.384] [Cited by in Crossref: 38] [Cited by in F6Publishing: 38] [Article Influence: 5.4] [Reference Citation Analysis]
319 Sagnelli C, Macera M, Pisaturo M, Zampino R, Coppola M, Sagnelli E. Occult HBV infection in the oncohematological setting. Infection. 2016;44:575-582. [PMID: 27076347 DOI: 10.1007/s15010-016-0891-1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
320 El-Ghitany EM, Farghaly AG, Hashish MH. Occult hepatitis B virus infection among hepatitis C virus seropositive and seronegative blood donors in Alexandria, Egypt. J Egypt Public Health Assoc. 2013;88:8-13. [PMID: 23528526 DOI: 10.1097/01.epx.0000422774.29308.b3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
321 Donato F, Gelatti U, Limina RM, Fattovich G. Southern Europe as an example of interaction between various environmental factors: a systematic review of the epidemiologic evidence. Oncogene. 2006;25:3756-3770. [PMID: 16799617 DOI: 10.1038/sj.onc.1209557] [Cited by in Crossref: 84] [Cited by in F6Publishing: 83] [Article Influence: 5.6] [Reference Citation Analysis]
322 Forns X, Sánchez Tapias JM, Parés A, Llovet JM, Bruix J, Rodés J. Expected developments in hepatology. Best Practice & Research Clinical Gastroenterology 2002;16:957-70. [DOI: 10.1053/bega.2002.0341] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
323 Pak K, Ordway S, Torres D. Occult HBV Infection: A Case Series at a Military Treatment Facility. Mil Med 2020;185:e795-8. [PMID: 31681958 DOI: 10.1093/milmed/usz379] [Reference Citation Analysis]
324 Bo J, Wang X, Li J, Wang W, Zhang J. Consecutive stimulation of HBsAg promotes the viability of the human B lymphoblastoid cell line IM-9 through regulating the SIRT1-NF-κB pathway. Oncol Lett 2017;14:433-40. [PMID: 28693188 DOI: 10.3892/ol.2017.6114] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
325 Durro V, Qyra S. Trends in prevalence of hepatitis B virus infection among Albanian blood donors, 1999-2009. Virol J 2011;8:96. [PMID: 21375724 DOI: 10.1186/1743-422X-8-96] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
326 Bharadwaj M, Roy G, Dutta K, Misbah M, Husain M, Hussain S. Tackling hepatitis B virus-associated hepatocellular carcinoma--the future is now. Cancer Metastasis Rev. 2013;32:229-268. [PMID: 23114844 DOI: 10.1007/s10555-012-9412-6] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
327 Squadrito G, Pollicino T, Cacciola I, Caccamo G, Villari D, La Masa T, Restuccia T, Cucinotta E, Scisca C, Magazzu D, Raimondo G. Occult hepatitis B virus infection is associated with the development of hepatocellular carcinoma in chronic hepatitis C patients: Occult HBV and HCC. Cancer 2006;106:1326-30. [DOI: 10.1002/cncr.21702] [Cited by in Crossref: 97] [Cited by in F6Publishing: 97] [Article Influence: 6.5] [Reference Citation Analysis]
328 Chen C, Changchien C, Lee C, Tung W, Hung C, Hu T, Wang J, Wang J, Lu S. A study on sequence variations in pre-S/surface, X and enhancer II/core promoter/precore regions of occult hepatitis B virus in non-B, non-C hepatocellular carcinoma patients in Taiwan. Int J Cancer 2009;125:621-9. [DOI: 10.1002/ijc.24416] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 2.3] [Reference Citation Analysis]
329 Sosa-Jurado F, Hilda Rosas-Murrieta N, Guzman-Flores B, Perez Zempoaltecalt C, Patricia Sanchez Torres A, Ramirez Rosete L, Bernal-Soto M, Marquez-Dominguez L, Melendez-Mena D, Angel Mendoza Torres M, Teresa Lopez Delgado M, Reyes-Leyva J, Vallejo-Ruiz V, Santos-Lopez G. Prevalence of Serologic Hepatitis B Markers in Blood Donors From Puebla, Mexico: The Association of Relatively High Levels of Anti-Core Antibodies With the Detection of Surface Antigen and Genomic DNA. Hepat Mon 2016;16:e36942. [PMID: 27630726 DOI: 10.5812/hepatmon.36942] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
330 Liang SH, Chen TJ, Lee SS, Tseng FC, Huang CK, Lai CH, Chiou CP, Wang JL, Chung HC, Lin JN. Risk factors of isolated antibody against core antigen of hepatitis B virus: association with HIV infection and age but not hepatitis C virus infection. J Acquir Immune Defic Syndr. 2010;54:122-128. [PMID: 20386111 DOI: 10.1097/qai.0b013e3181daafd5] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
331 Esposito A, Sabia C, Iannone C, Nicoletti GF, Sommese L, Napoli C. Occult Hepatitis Infection in Transfusion Medicine: Screening Policy and Assessment of Current Use of Anti-HBc Testing. Transfus Med Hemother 2017;44:263-72. [PMID: 28924431 DOI: 10.1159/000460301] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
332 Ozoya OO, Sokol L, Dalia S. Hepatitis B Reactivation with Novel Agents in Non-Hodgkin's Lymphoma and Prevention Strategies. J Clin Transl Hepatol 2016;4:143-50. [PMID: 27350944 DOI: 10.14218/JCTH.2016.00005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
333 Kalantari H, Ferdowsi F, Yaran M. Prevalence of occult hepatitis B virus infection in hemodialysis patients in Isfahan, Iran. Adv Biomed Res 2016;5:151. [PMID: 27713872 DOI: 10.4103/2277-9175.188487] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
334 Liu C, Chen P, Chen D, Kao J. Hepatitis B virus reactivation in patients receiving cancer chemotherapy: natural history, pathogenesis, and management. Hepatol Int 2013;7:316-26. [DOI: 10.1007/s12072-011-9279-6] [Cited by in Crossref: 32] [Cited by in F6Publishing: 35] [Article Influence: 3.2] [Reference Citation Analysis]
335 Kim SJ, Moon JH, Kim H, Kim JS, Hwang YY, Intragumtornchai T, Issaragrisil S, Kwak JY, Lee JJ, Won JH. Non-bacterial infections in Asian patients treated with alemtuzumab: a retrospective study of the Asian Lymphoma Study Group. Leuk Lymphoma. 2012;53:1515-1524. [PMID: 22273250 DOI: 10.3109/10428194.2012.659735] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 2.6] [Reference Citation Analysis]
336 Stratta P, Bruschetta E, Minisini R, Barbè MC, Cornella C, Tognarelli G, Cena T, Magnani C, Fenoglio R, Toffolo K, Airoldi A, Pirisi M. Prevalence and clinical relevance of occult hepatitis B virus infection in patients on the waiting list for kidney transplantation. Transplant Proc 2009;41:1132-7. [PMID: 19460498 DOI: 10.1016/j.transproceed.2009.03.001] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
337 Bruix J, Llovet JM. Hepatitis B virus and hepatocellular carcinoma. J Hepatol 2003;39 Suppl 1:S59-63. [PMID: 14708679 DOI: 10.1016/s0168-8278(03)00140-5] [Cited by in Crossref: 70] [Cited by in F6Publishing: 23] [Article Influence: 4.1] [Reference Citation Analysis]
338 Ramia S, Mokhbat J, Ramlawi F, El-Zaatari M. Occult hepatitis B virus infection in HIV-infected Lebanese patients with isolated antibodies to hepatitis B core antigen. Int J STD AIDS. 2008;19:197-199. [PMID: 18397562 DOI: 10.1258/ijsa.2007.007200] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
339 Wang Q, Klenerman P, Semmo N. Significance of anti-HBc alone serological status in clinical practice. The Lancet Gastroenterology & Hepatology 2017;2:123-34. [DOI: 10.1016/s2468-1253(16)30076-0] [Cited by in Crossref: 21] [Cited by in F6Publishing: 3] [Article Influence: 5.3] [Reference Citation Analysis]
340 Pollicino T, Musolino C, Saitta C, Tripodi G, Lanza M, Raffa G, Tocco FCD, Raggi C, Bragazzi MC, Barbera A, Navarra G, Invernizzi P, Alvaro D, Raimondo G. Free episomal and integrated HBV DNA in HBsAg-negative patients with intrahepatic cholangiocarcinoma. Oncotarget. 2019;10:3931-3938. [PMID: 31231470 DOI: 10.18632/oncotarget.27002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
341 Alavian SM, Carman WF, Jazayeri SM. HBsAg variants: diagnostic-escape and diagnostic dilemma. J Clin Virol. 2013;57:201-208. [PMID: 22789139 DOI: 10.1016/j.jcv.2012.04.027] [Cited by in Crossref: 54] [Cited by in F6Publishing: 47] [Article Influence: 6.0] [Reference Citation Analysis]
342 Wang H, Fang M, Gu X, Ji Q, Li D, Cheng SQ, Shen F, Gao CF. The intracellular HBV DNAs as novel and sensitive biomarkers for the clinical diagnosis of occult HBV infection in HBeAg negative hepatocellular carcinoma in China. PLoS One. 2014;9:e107162. [PMID: 25229710 DOI: 10.1371/journal.pone.0107162] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
343 Kew MC, Welschinger R, Viana R. Occult hepatitis B virus infection in Southern African blacks with hepatocellular carcinoma. J Gastroenterol Hepatol. 2008;23:1426-1430. [PMID: 18853999 DOI: 10.1111/j.1440-1746.2008.05481.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
344 Cho EJ, Yu SJ, Kwon SY, Kim JH, Kim DY, Kim W, Lee JS, Lee JW, Lee YJ, Chae HB, Yoon JH. Concomitant food intake does not affect the efficacy of entecavir in chronic hepatitis B patients with virological response: a randomized, multicenter, noninferiority trial. Drug Des Devel Ther 2018;12:3767-74. [PMID: 30464407 DOI: 10.2147/DDDT.S181561] [Reference Citation Analysis]
345 Yoo JH, Hwang SG, Yang DH, Son MS, Kwon CI, Ko KH, Hong SP, Park PW, Rim KS. Prevalence of occult hepatitis B virus infection in hemodialysis patients. Korean J Gastroenterol 2013;61:209-14. [PMID: 23624735 DOI: 10.4166/kjg.2013.61.4.209] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
346 Hashemi SJ, Hajiani E, Masjedizadeh A, Makvandi M, Shayesteh AA, Alavinejad SP, Kadkhodaei A, Shahbazian H, Jasemi F, Karimi M. Occult hepatitis B infection in patients with cryptogenic liver cirrhosis in southwest of Iran. Jundishapur J Microbiol. 2015;8:e16873. [PMID: 25861432 DOI: 10.5812/jjm.16873] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
347 Panigrahi R, Majumder S, Gooptu M, Biswas A, Datta S, Chandra P, Banerjee A, Chakrabarti S, Bandopadhyay D, De B, Chakravarty R. Occult HBV infection among anti-HBc positive HIV-infected patients in apex referral centre, Eastern India. Annals of Hepatology 2012;11:870-5. [DOI: 10.1016/s1665-2681(19)31412-7] [Cited by in Crossref: 14] [Article Influence: 1.6] [Reference Citation Analysis]
348 Pompili M, Basso M, Hohaus S, Bosco G, Nosotti L, D’andrea M, Fenu S, Grieco A, Laurenti L, Mirisola C, Pagano L, Rapaccini GL, Sica S, Storti S, Landolfi R. Prospective study of hepatitis B virus reactivation in patients with hematological malignancies. Annals of Hepatology 2015;14:168-74. [DOI: 10.1016/s1665-2681(19)30778-1] [Cited by in Crossref: 9] [Article Influence: 1.5] [Reference Citation Analysis]
349 Dalia S, Chavez J, Castillo JJ, Sokol L. Hepatitis B infection increases the risk of non-Hodgkin lymphoma: A meta-analysis of observational studies. Leukemia Research 2013;37:1107-15. [DOI: 10.1016/j.leukres.2013.06.007] [Cited by in Crossref: 45] [Cited by in F6Publishing: 45] [Article Influence: 5.6] [Reference Citation Analysis]
350 Seto WK, Tanaka Y, Wong DK, Lai CL, Shinkai N, Yuen JC, Tong T, Fung J, Hung IF, Yuen MF. Evidence of serologic activity in chronic hepatitis B after surface antigen (HBsAg) seroclearance documented by conventional HBsAg assay. Hepatol Int 2012;7:98-105. [PMID: 24014110 DOI: 10.1007/s12072-012-9354-7] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
351 Indolfi G, Nesi A, Resti M. Treatment of chronic hepatitis B and C in children. Future Virology 2012;7:955-72. [DOI: 10.2217/fvl.12.94] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
352 El-Maksoud MA, Habeeb MR, Ghazy HF, Nomir MM, Elalfy H, Abed S, Zaki MES. Clinicopathological study of occult hepatitis B virus infection in hepatitis C virus-associated hepatocellular carcinoma. Eur J Gastroenterol Hepatol. 2019;31:716-722. [PMID: 30870221 DOI: 10.1097/meg.0000000000001388] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 6.0] [Reference Citation Analysis]
353 Shahmoradi S, Yahyapour Y, Mahmoodi M, Alavian SM, Fazeli Z, Jazayeri SM. High prevalence of occult hepatitis B virus infection in children born to HBsAg-positive mothers despite prophylaxis with hepatitis B vaccination and HBIG. J Hepatol. 2012;57:515-521. [PMID: 22617152 DOI: 10.1016/j.jhep.2012.04.021] [Cited by in Crossref: 72] [Cited by in F6Publishing: 65] [Article Influence: 8.0] [Reference Citation Analysis]
354 Maklad S, Reyad EM, William EA, Abouzeid A. Efficacy and Safety of Entecavir 0. 5 mg in Treating Naive Chronic Hepatitis B Virus Patients in Egypt: Five Years of Real Life Experience. Gastroenterology Res 2018;11:138-44. [PMID: 29707081 DOI: 10.14740/gr965w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
355 Chakravarty R. Role of molecular diagnostics in the management of viral hepatitis B. Expert Opin Med Diagn 2012;6:395-406. [PMID: 23480805 DOI: 10.1517/17530059.2012.690391] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
356 Kew MC. Hepatocellular carcinoma in African Blacks: Recent progress in etiology and pathogenesis. World J Hepatol 2010;2:65-73. [PMID: 21160975 DOI: 10.4254/wjh.v2.i2.65] [Cited by in Crossref: 36] [Cited by in F6Publishing: 31] [Article Influence: 3.6] [Reference Citation Analysis]
357 Allain J. Occult hepatitis B virus infection. Transfusion Clinique et Biologique 2004;11:18-25. [DOI: 10.1016/j.tracli.2003.11.007] [Cited by in Crossref: 92] [Cited by in F6Publishing: 89] [Article Influence: 5.4] [Reference Citation Analysis]
358 Coffin CS, Stock PG, Dove LM, Berg CL, Nissen NN, Curry MP, Ragni M, Regenstein FG, Sherman KE, Roland ME. Virologic and clinical outcomes of hepatitis B virus infection in HIV-HBV coinfected transplant recipients. Am J Transplant. 2010;10:1268-1275. [PMID: 20346065 DOI: 10.1111/j.1600-6143.2010.03070.x] [Cited by in Crossref: 70] [Cited by in F6Publishing: 51] [Article Influence: 6.4] [Reference Citation Analysis]
359 Coffin CS, Mulrooney-Cousins PM, Osiowy C, van der Meer F, Nishikawa S, Michalak TI, van Marle G, Gill MJ. Virological characteristics of occult hepatitis B virus in a North American cohort of human immunodeficiency virus type 1-positive patients on dual active anti-HBV/HIV therapy. J Clin Virol. 2014;60:347-353. [PMID: 24881491 DOI: 10.1016/j.jcv.2014.04.021] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 2.4] [Reference Citation Analysis]
360 McLaughlin-Drubin ME, Munger K. Viruses associated with human cancer. Biochim Biophys Acta 2008;1782:127-50. [PMID: 18201576 DOI: 10.1016/j.bbadis.2007.12.005] [Cited by in Crossref: 203] [Cited by in F6Publishing: 151] [Article Influence: 14.5] [Reference Citation Analysis]
361 Chakravarty R, Neogi M, Roychowdhury S, Panda CK. Presence of hepatitis B surface antigen mutant G145R DNA in the peripheral blood leukocytes of the family members of an asymptomatic carrier and evidence of its horizontal transmission. Virus Res. 2002;90:133-141. [PMID: 12457969 DOI: 10.1016/s0168-1702(02)00147-8] [Cited by in Crossref: 35] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
362 Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet. 2012;379:1245-1255. [PMID: 22353262 DOI: 10.1016/s0140-6736(11)61347-0] [Cited by in Crossref: 2892] [Cited by in F6Publishing: 1601] [Article Influence: 321.3] [Reference Citation Analysis]
363 Knöll A, Hartmann A, Hamoshi H, Weislmaier K, Jilg W. Serological pattern "anti-HBc alone": characterization of 552 individuals and clinical significance. World J Gastroenterol 2006;12:1255-60. [PMID: 16534880 DOI: 10.3748/wjg.v12.i8.1255] [Cited by in CrossRef: 45] [Cited by in F6Publishing: 41] [Article Influence: 3.0] [Reference Citation Analysis]
364 Ramezani A, Mohraz M, Aghakhani A, Banifazl M, Eslamifar A, Khadem-Sadegh A, Velayati AA. Frequency of isolated hepatitis B core antibody in HIV-hepatitis C virus co-infected individuals. Int J STD AIDS. 2009;20:336-338. [PMID: 19386971 DOI: 10.1258/ijsa.2008.008377] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
365 Ayana DA, Mulu A, Mihret A, Seyoum B, Aseffa A, Howe R. Occult Hepatitis B virus infection among HIV negative and positive isolated anti-HBc individuals in eastern Ethiopia. Sci Rep 2020;10:22182. [PMID: 33335238 DOI: 10.1038/s41598-020-79392-x] [Reference Citation Analysis]
366 Jang JY, Jeong SW, Cheon SR, Lee SH, Kim SG, Cheon YK, Kim YS, Cho YD, Kim HS, Jin SY. Clinical significance of occult hepatitis B virus infection in chronic hepatitis C patients. Korean J Hepatol. 2011;17:206-212. [PMID: 22102387 DOI: 10.3350/kjhep.2011.17.3.206] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
367 Raimondo G, Pollicino T, Squadrito G. What is the clinical impact of occult hepatitis B virus infection? Lancet. 2005;365:638-640. [PMID: 15721459 DOI: 10.1016/s0140-6736(05)17961-6] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
368 Valsamakis A. Molecular testing in the diagnosis and management of chronic hepatitis B. Clin Microbiol Rev. 2007;20:426-439, table of contents. [PMID: 17630333 DOI: 10.1128/cmr.00009-07] [Cited by in Crossref: 86] [Cited by in F6Publishing: 31] [Article Influence: 6.1] [Reference Citation Analysis]
369 Wolff FH, Fuchs SC, Brandão AB. Absence of occult hepatitis B among blood donors in southern Brazil. The Brazilian Journal of Infectious Diseases 2011;15:159-62. [DOI: 10.1016/s1413-8670(11)70163-5] [Cited by in Crossref: 5] [Article Influence: 0.5] [Reference Citation Analysis]
370 Sagnelli E, Pisaturo M, Martini S, Filippini P, Sagnelli C, Coppola N. Clinical impact of occult hepatitis B virus infection in immuno–suppressed patients. World J Hepatol. 2014;6:384-393. [PMID: 25018849 DOI: 10.4254/wjh.v6i6.384] [Reference Citation Analysis]
371 Kao JH, Chen PJ, Lai MY, Chen DS. Occult hepatitis B virus infection and clinical outcomes of patients with chronic hepatitis C. J Clin Microbiol. 2002;40:4068-4071. [PMID: 12409376 DOI: 10.1128/jcm.40.11.4068-4071.2002] [Cited by in Crossref: 103] [Cited by in F6Publishing: 26] [Article Influence: 5.7] [Reference Citation Analysis]
372 Mulrooney PM, Michalak TI. Quantitative detection of hepadnavirus-infected lymphoid cells by in situ PCR combined with flow cytometry: implications for the study of occult virus persistence. J Virol. 2003;77:970-979. [PMID: 12502813 DOI: 10.1128/jvi.77.2.970-979.2003] [Cited by in Crossref: 19] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
373 Said ZN. An overview of occult hepatitis B virus infection. World J Gastroenterol. 2011;17:1927-1938. [PMID: 21528070 DOI: 10.3748/wjg.v17.i15.1927] [Cited by in CrossRef: 96] [Cited by in F6Publishing: 83] [Article Influence: 9.6] [Reference Citation Analysis]
374 Stolz M, Tinguely C, Fontana S, Niederhauser C. Hepatitis B virus DNA viral load determination in hepatitis B surface antigen-negative Swiss blood donors: Sensitivity Limit for HBV DNA in Blood Donors. Transfusion 2014;54:2961-7. [DOI: 10.1111/trf.12694] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
375 Wu ZF, Xu Z, Li WS, Zhang HB, Yang N, Yao XQ, Liu FK, Yang GS. Impact of occult hepatitis B virus infection on outcome after resection for non-B non-C hepatocellular carcinoma. J Surg Res 2015;193:153-60. [PMID: 25128925 DOI: 10.1016/j.jss.2014.07.021] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
376 Shang G, Yan Y, Yang B, Shao C, Wang F, Li Q, Seed CR. Two HBV DNA+/HBsAg- blood donors identified by HBV NAT in Shenzhen, China. Transfus Apher Sci 2009;41:3-7. [PMID: 19487161 DOI: 10.1016/j.transci.2009.05.001] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
377 Schiefelbein E, Zekri AR, Newton DW, Soliman GA, Banerjee M, Hung ChW, Seifeldin IA, Lo AC, Soliman AS. Hepatitis C virus and other risk factors in hepatocellular carcinoma. Acta Virol 2012;56:235-40. [PMID: 23043603 DOI: 10.4149/av_2012_03_235] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
378 Shetty K, Hussain M, Nei L, Reddy KR, Lok AS. Prevalence and significance of occult hepatitis B in a liver transplant population with chronic hepatitis C. Liver Transpl. 2008;14:534-540. [PMID: 18324677 DOI: 10.1002/lt.21284] [Cited by in Crossref: 45] [Cited by in F6Publishing: 44] [Article Influence: 3.5] [Reference Citation Analysis]
379 Fabrizi F, Bunnapradist S, Lunghi G, Villa M, Martin P. Transplanting Solid Organs from HBsAg Negative Donors Positive for Antibody to Hepatitis B Core Antigen: The Implications. The International Journal of Artificial Organs 2018;26:972-83. [DOI: 10.1177/039139880302601102] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
380 Torisu Y, Ikeda K, Kobayashi M, Hosaka T, Sezaki H, Akuta N, Kawamura Y, Yatsuji H, Suzuki F, Suzuki Y, Arase Y, Kumada H. Diabetes mellitus increases the risk of hepatocarcinogenesis in patients with alcoholic cirrhosis: A preliminary report. Hepatol Res. 2007;37:517-523. [PMID: 17539994 DOI: 10.1111/j.1872-034x.2007.00077.x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
381 Fang Y, Shang Q, Liu J, Li D, Xu W, Teng X, Zhao H, Fu L, Zhang F, Gu H. Prevalence of occult hepatitis B virus infection among hepatopathy patients and healthy people in China. Journal of Infection 2009;58:383-8. [DOI: 10.1016/j.jinf.2009.02.013] [Cited by in Crossref: 54] [Cited by in F6Publishing: 61] [Article Influence: 4.5] [Reference Citation Analysis]